

1 **Systems genetics uncover new loci containing functional gene candidates in *Mycobacterium***
2 ***tuberculosis*-infected Diversity Outbred mice.**

3 Gatti DM¹, Tyler AL¹, Mahoney JM¹, Churchill GA¹, Yener B², Koyuncu D², Gurcan MN³, Niazi MKK³,
4 Tavolara T³, Gower AC⁶, Dayao D⁷, McGlone E⁷, Ginese ML⁷, Specht A⁷, Alsharaydeh A⁹, Tessier PA⁸,
5 Kurtz SL⁴, Elkins K⁴, Kramnik I⁵, Beamer G⁹.

6

7 **AFFILIATIONS**

8 ¹ The Jackson Laboratory, Bar Harbor, ME

9 ² Rensselaer Polytechnic Institute, Troy, NY

10 ³ Wake Forest University School of Medicine, Winston Salem, NC

11 ⁴ Center for Biologics, Food and Drug Administration, Bethesda, MD

12 ⁵ NIEDL, Boston University, Boston, MA

13 ⁶ Clinical and Translational Science Institute, Boston University, Boston, MA

14 ⁷ Tufts University Cummings School of Veterinary Medicine, North Grafton, MA

15 ⁸ Department of Microbiology and Immunology, Laval University School of Medicine, Quebec, Canada

16 ⁹ Texas Biomedical Research Institute, San Antonio, TX

17

19 **ABSTRACT**

20 *Mycobacterium tuberculosis*, the bacillus that causes tuberculosis (TB), infects 2 billion people across
21 the globe, and results in 8-9 million new TB cases and 1-1.5 million deaths each year. Most patients have
22 no known genetic basis that predisposes them to disease. We investigated the complex genetic basis of
23 pulmonary TB by modelling human genetic diversity with the Diversity Outbred mouse population. When
24 infected with *M. tuberculosis*, one-third develop early onset, rapidly progressive, necrotizing granulomas
25 and succumb within 60 days. The remaining develop non-necrotizing granulomas and survive longer than
26 60 days. Genetic mapping using clinical indicators of disease, granuloma histopathological features, and
27 immune response traits identified five new loci on mouse chromosomes 1, 2, 4, 16 and three previously
28 identified loci on chromosomes 3 and 17. Quantitative trait loci (QTLs) on chromosomes 1, 16, and 17,
29 associated with multiple correlated traits and had similar patterns of allele effects, suggesting these QTLs
30 contain important genetic regulators of responses to *M. tuberculosis*. To narrow the list of candidate
31 genes in QTLs, we used a machine learning strategy that integrated gene expression signatures from
32 lungs of *M. tuberculosis*-infected Diversity Outbred mice with gene interaction networks, generating
33 functional scores. The scores were then used to rank candidates for each mapped trait in each locus,
34 resulting in 11 candidates: *Ncf2*, *Fam20b*, *S100a8*, *S100a9*, *Itgb5*, *Fstl1*, *Zbtb20*, *Ddr1*, *Ier3*, *Vegfa*, and
35 *Zfp318*. Importantly, all 11 candidates have roles in infection, inflammation, cell migration, extracellular
36 matrix remodeling, or intracellular signaling. Further, all candidates contain single nucleotide
37 polymorphisms (SNPs), and some but not all SNPs were predicted to have deleterious consequences on
38 protein functions. Multiple methods were used for validation including (i) a statistical method that showed
39 Diversity Outbred mice carrying PWH/PhJ alleles on chromosome 17 QTL have shorter survival; (ii)
40 quantification of S100A8 protein levels, confirming predicted allele effects; and (iii) infection of C57BL/6
41 mice deficient for the *S100a8* gene. Overall, this work demonstrates that systems genetics using Diversity
42 Outbred mice can identify new (and known) QTLs and new functionally relevant gene candidates that
43 may be major regulators of granuloma necrosis and acute inflammation in pulmonary TB.

44 **AUTHOR SUMMARY**

45 We investigated the genetic basis of susceptibility to *Mycobacterium tuberculosis* using Diversity Outbred
46 mice, a mouse population suited for studies on complex genotype-phenotype relationships. We identified
47 multiple new genetic loci as well as two previously identified loci. Interestingly, we found three loci
48 associated with multiple disease traits, which indicates genes within the loci are likely major regulators of
49 host inflammatory responses which permit *M. tuberculosis* growth. These three loci contain at least four
50 gene candidates with single nucleotide polymorphisms that are predicted to have deleterious effects upon
51 protein functions.

52

53

54 **INTRODUCTION**

55 The number of humans who develop active pulmonary tuberculosis (TB) is small compared to those
56 who eliminate or control *Mycobacterium tuberculosis* (5-10% vs 90-95%), yet morbidity and mortality from
57 TB remain high. Although COVID-19 mortality temporarily surpassed global TB mortality, TB has
58 remained in the top two leading causes of death due to an infectious disease for decades, killing more
59 people than HIV/AIDS and malaria. Pulmonary TB is the most common and most contagious form of TB,
60 with mortality rates >40% if untreated or if caused by antibiotic resistant *M. tuberculosis* [1-8]. Human
61 responses to *M. tuberculosis* infection range from fulminant pulmonary TB that develops within weeks to
62 lifelong control of latent infection or complete clearance of bacilli [9-11]. Further, a body of evidence
63 shows an interesting paradox: Immune competence is necessary to restrict *M. tuberculosis* growth [12],
64 but is not sufficient to prevent disease [13].

65 The variable responses to *M. tuberculosis* and lack of single genetic defects in most patients indicate
66 a complex genetic basis for pulmonary TB, and this has been investigated by linkage association
67 mapping, genome-wide association studies, and other methods, recently reviewed [14-17]. These
68 reviews frequently identify knowledge gaps attributable to the observations that the most used laboratory
69 mouse strains do not replicate key disease traits (e.g., granuloma necrosis) of human pulmonary TB [18-]

70 23]. To address these gaps, we and others use the Diversity Outbred mouse population and Collaborative
71 Cross recombinant inbred strains [24-26], some of which do develop human-like pulmonary TB following
72 *M. tuberculosis* infection. These mice provide valuable resources to model complex genotype-phenotype
73 associations; tools to dissect the genetic basis of disease; and a means to test for effects of candidate
74 genetic polymorphisms *in vivo*.

75 The Diversity Outbred mouse population originated by breeding eight inbred founder strains together,
76 resulting in an experimental population with balanced allele frequencies of one-eighth across the genome
77 [27]. This is important for genetic mapping studies because low allele frequencies in natural populations
78 can diminish power and increase false positive findings [28]. Further, Diversity Outbred mice carry over
79 40 million variants [29], some of which alter regulatory elements, splice sites, and protein-coding
80 sequences. This defined genetic architecture allows rigorous investigation of genotype-phenotype
81 association in context of *M. tuberculosis* infection.

82 Here, to find genetic loci associated with pulmonary TB, we used quantitative trait locus (QTL)
83 mapping. Next we ranked candidate genes within the *Diversity Outbred tuberculosis susceptibility (Dots)*
84 loci that were associated with correlated, colocalized traits by using a machine learning algorithm [30,
85 31] to find genes functionally related to the mapped traits and the fit models scored each candidate [32].
86 All candidates contain a variety of SNPs as annotated in Mouse Variation Registry (MVAR). Seven of the
87 eleven candidates contain missense SNPs in protein coding regions, and of those, the SNPs in four
88 candidates (*S100a8*, *Itgb5*, *Fstl1*, and *Zfp318*) are predicted to have deleterious consequences on protein
89 functions.

90 Published studies have shown three candidates (*Itgb5*, *Fstl1*, *S100a8*) involved in bacterial lung
91 diseases that includes *in vitro*, or *in vivo* *M. tuberculosis* infection [33-39]. The other eight candidates
92 have no known roles in *M. tuberculosis* infection but have been shown in other systems to contribute to
93 cell stress responses, signaling pathways, adhesion and migration; extracellular matrix synthesis, tissue
94 remodeling and angiogenesis; immune cell metabolism; macrophage inflammatory responses; and viral
95 hepatitis [40-52]. Overall, ten candidate genes have roles in innate immune responses suggesting that

96 genetically controlled responses of epithelial and endothelial cells, neutrophils, and monocytes,
97 macrophages to *M. tuberculosis* bacilli are the primary drivers of susceptibility to *M. tuberculosis* and to
98 disease progression in pulmonary TB. Only 1 candidate has a direct role in acquired, antigen-specific
99 immunity.

100

101 **METHODS**

102 **Ethics Statement**

103 Tufts University's Institutional Animal Care and Use Committee (IACUC) approved this work under
104 protocols G2012-53; G2015-33; G2018-33; and G2020-121. Tufts University's Institutional Biosafety
105 Committee (IBC) approved this work under registrations: GRIA04; GRIA10; GRIA17, and 2020-G61.

106

107 **Mice**

108 Female Diversity Outbred mice (n=850) from generations 15 16, 21, 22, 34, 35, 37 and 42 and the inbred
109 founder strains: A/J, C57BL/6J, 129S1/SvImJ, NOD/LtJ, NZO/HILtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ
110 mice (n=15-59 per strain) were purchased from The Jackson Laboratory (Bar Harbor, ME) and group
111 housed (n=5-7 mice per cage) on Innovive (San Diego, CA) or Allentown Inc (Allentown, NJ) ventilated,
112 HEPA-filtered racks in the New England Regional Biosafety Laboratory (Tufts University, Cummings
113 School of Veterinary Medicine, North Grafton, MA) or at The Ohio State University Columbus, OH. The
114 light cycle was 12 hours of light; 12 hours of dark. Two breeding pairs of female and male C57BL/6 inbred
115 mice carrying null mutation for *S100a8* gene were a kind gift of Dr. Philippe Tessier, Department of
116 Microbiology and Immunology, Faculty of Medicine, Université Laval. After quarantine, breeders were
117 used to establish a colony of *S100a8* homozygous knock out (KO), heterozygous (HET) and wild-type
118 (WT) C57BL/6 inbred mice. Mice were housed in disposable sterile caging or re-usable autoclaved caging
119 containing sterile corn-cob bedding, with sterile paper nestlets (Scotts Pharma Solutions, Marlborough,
120 MA), and/or sterile enrichment paperboard or plastic "houses". Cages were changed every other week

121 or sooner if soiled. Mice were provided with sterile mouse chow (Envigo, Indianapolis, IA) and sterile,
122 acidified water *ad libidum*.

123

124 ***M. tuberculosis* Aerosol Infection**

125 Female Diversity Outbred mice and inbred founder strains were infected with aerosolized *M. tuberculosis*
126 strain Erdman bacilli using a custom-built CH Technologies system [24, 39, 53] or a Glas-col (Terre
127 Haute, ID) system [54, 55] between eight and ten weeks of age. Male and female C57BL/6 S100a8 KO,
128 HET, and WT mice were infected between eight and sixteen weeks of age. For each aerosol infection,
129 the retained lung dose was determined by euthanizing a cohort of four to twelve mice 24 hours after
130 exposure, homogenizing the entire lungs in 5mL sterile phosphate buffered saline, and plating the entire
131 homogenate onto OADC-supplemented 7H11 agar. After 3-4 weeks at 37°C, *M. tuberculosis* colony
132 forming units were counted. Mice were infected with ~100 colony forming units in the first two
133 experiments, and ~25 colony forming units in the subsequent eight experiments.

134

135 ***Quantification of TB-related Traits (Phenotyping)***

136 *Survival*. IACUC protocols disallowed natural death as an endpoint. Therefore, as a proxy of survival, we
137 used the day of euthanasia due to any single criterion: Severe weakness/lethargy; or respiratory distress;
138 or body condition score < 2 [56]. We confirmed morbidity was due to pulmonary TB by finding: (i) Large
139 nodular, or severe diffuse lung lesions; (ii) histopathology confirmation of severe granulomatous lung
140 infiltrates; (iii) growth of viable *M. tuberculosis* colonies from lung tissue; and (iv) absence of other
141 diseases. Twenty-one *M. tuberculosis* infected Diversity Outbred mice were excluded due to co-morbidity
142 that developed during the experiment.

143

144 *Weight loss*. Mice were weighed 1 to 3 days prior to *M. tuberculosis* aerosol infection, at least once per
145 week during infection, and immediately before euthanasia. For each mouse, weight loss was calculated
146 as the percent loss from peak body weight.

147

148 *Lung granuloma necrosis.* Immediately after euthanasia, lung lobes were removed and inflated and fixed
149 in 10% neutral buffered formalin (5-10 mL per lobe), processed, and embedded in paraffin, sectioned at
150 5 μ m, and stained with hematoxylin and eosin with or without carbol fuschin for acid-fast bacilli at Tufts
151 University, Cummings School of Veterinary Medicine, Core Histology Laboratory (North Grafton, MA).
152 Hematoxylin and eosin-stained glass slides were magnified 400 times and digitally scanned by Aperio,
153 LLC (Sausalito, CA) ScanScope scanners at 0.23 microns per pixel at The Ohio State University's
154 Comparative Pathology and Mouse Phenotyping Shared Resources Core resource (Columbus, OH) or
155 by Aperio, LLC (Sausalito, CA) AT2 scanners at 0.23 microns per pixel at Vanderbilt University Medical
156 Center's Digital Histology Shared Resource (Nashville, TN). Lung granuloma necrosis was quantified in
157 one lung lobe per mouse by our previously validated, deep learning image analysis method [57] and
158 reported here as a ratio of granuloma necrosis per lung tissue area.

159

160 *M. tuberculosis lung burden.* Immediately after euthanasia, 2 or 3 lung lobes were removed from each
161 mouse and homogenized in sterile phosphate buffered saline (1mL per lobe), serially diluted, plated onto
162 OADC-supplemented 7H11 agar, incubated at 37°C for 3-4 weeks, after which colonies were counted,
163 and *M. tuberculosis* lung burden in the lungs was calculated as described [58].

164

165 *Lung cytokines and chemokines.* Lung homogenates were stored at -80°C until the experiment ended.
166 Lung homogenates were then thawed overnight at 4° serially diluted and tested for CXCL5, CXCL2,
167 CXCL1, tumor necrosis factor (TNF), matrix metalloproteinase 8 (MMP8), S100A8, interferon-gamma
168 (IFN- γ), interleukin (IL)-12p40, IL-12p70, IL-10, and vascular endothelial growth factor (VEGF) by
169 sandwich ELISA using antibody pairs and standards from R&D Systems (Minneapolis, MN), Invitrogen
170 (Carlsbad, CA), eBioscience (San Diego, CA), or BD Biosciences (San Jose, CA, USA), per kit
171 instructions. Lung homogenate ELISA results from five of the experiments using Diversity Outbred mice
172 have been published and analyzed for biomarkers previously [39].

173

174 ***Phenotype Correlation***

175 We took the log of each phenotype after adding one (to ensure that zero was not converted to negative
176 infinity) and regressed out the effect of the experimental batch. We then standardized the residuals and
177 estimated the Pearson correlation between all pairs of phenotypes.

178

179 ***Gene Expression***

180 One lung lobe from 98 Diversity Outbred mice was homogenized in TRIzol, stored at -80°C, and RNA
181 was extracted using Pure Link mini-kits (Life Technologies, Carlsbad, CA). Boston University's Microarray
182 and Sequencing Resource Core Facility (Boston, MA) confirmed quality and quantity were sufficient for
183 microarray analyses. Mouse Gene 2.0 ST CEL files were normalized to produce gene-level expression
184 values using the implementation of the Robust Multiarray Average (RMA) in the Affy package (version
185 1.62.0) included in the Bioconductor software suite and an Entrez Gene-specific probeset mapping
186 (17.0.0) from the Molecular and Behavioral Neuroscience Institute (Brainarray) at the University of
187 Michigan. Array quality was assessed by computing Relative Log Expression (RLE) and Normalized
188 Unscaled Standard Error (NUSE) using the affyPLM package (version 1.59.0). The CEL files were also
189 normalized using Expression Console (build 1.4.1.46) and the default probesets defined by Affymetrix to
190 assess array quality using an AUC metric computed from sets of negative and positive control probes;
191 all samples used in this analysis had an AUC > 0.8. Moderated *t*-tests and ANOVAs were performed
192 using the limma package (version 3.39.19) (i.e., creating simple linear models with lmFit, followed by
193 empirical Bayesian adjustment with eBayes). Correction for multiple hypothesis testing was
194 accomplished using the Benjamini-Hochberg false discovery rate (FDR). To remove microarray probes
195 that intersected with Diversity Outbred SNPs, we intersected the Diversity Outbred founder strain SNPs
196 [59] with the vendor-provided probes and removed probes containing SNPs. All microarray analyses
197 were performed using the R environment for statistical computing (version 3.6.0). A related microarray

198 dataset and other secondary analyses have been published elsewhere [39, 60] and deposited in Gene
199 Expression Omnibus (GEO), and assigned Series ID GSE179417.

200

201 ***Genotyping***

202 We collected tail tips from each Diversity Outbred mouse and sent them to Neogen (Lincoln, NE) for DNA
203 isolation and genotyping. Neogen genotyped the mice on the Illumina GigaMUGA platform, which
204 contains 143,259 markers [61]. Genotypes of *S100a8* KO, HET, and WT C57BL/6 inbred mice were
205 confirmed by polymerase chain reaction (TransnetYX, Cordova, TN).

206

207 ***Haplotype Reconstruction and SNP Imputation***

208 We used 137,302 GigaMUGA marker positions located on the autosomes and chromosome X found at
209 https://github.com/kbroman/MUGAarrays/blob/main/UWisc/gm_uwisc_v1.csv and the R package *qtL2* to
210 reconstruct the Diversity Outbred haplotypes using the founder and Diversity Outbred allele calls, and
211 used the haplotype reconstructions to impute the founder SNPs onto the Diversity Outbred genomes [62].

212

213 ***Quantitative Trait Locus Mapping***

214 We included Diversity Outbred mice that survived *M. tuberculosis* infection for 250 days or less because
215 age-related comorbidities began to appear and complicated interpretation. We used *qtL2* [62] to perform
216 linkage mapping using the founder haplotypes and association mapping using the imputed SNPs. We
217 calculated the kinship between mice using the leave-one-chromosome-out method, which excludes the
218 current chromosome in kinship calculations [63]. We standardized each phenotype and mapped with the
219 Diversity Outbred outbreeding generation as an additive covariate and used the linear mixed-effects
220 model with one kinship matrix per chromosome. We estimated the genome-wide significance thresholds
221 by permuting the samples 1,000 times and performed a genome scan with each permutation. We retained
222 the maximum \log_{10} of the odds ratio (LOD) score from each permutation and estimated the genome-wide
223 significance threshold of 7.6 from the 95th percentile of the empirical distribution of maximum LOD scores

224 under permutation. We estimated the support interval around each peak using the 95% Bayesian
225 Credible Interval.

226 For each peak with a LOD score above the genome-wide threshold > 7.6 , we then searched for
227 peaks associated with other traits that had LOD scores > 6 and confidence intervals that overlapped [64].
228 Our rationale was that the probability that a peak is biologically relevant, given that another trait has a
229 co-located peak, is higher than the probability that a peak is significant with no prior evidence.

230

231 ***Candidate Gene Selection***

232 Within each QTL interval, we imputed the founder SNPs onto the Diversity Outbred mouse genomes
233 using *qt2* and performed association mapping. We selected the SNPs that were within a 1 LOD drop of
234 the peak SNP in the QTL interval and filtered them to retain ones with missense, splice, or stop codon
235 effects as annotated by the Sanger Mouse Genome Project [59]. We considered the genes in which these
236 polymorphisms occurred as candidate causal genes for the associated trait(s).

237

238 ***Trait-related Gene Sets***

239 Because causal variants within a QTL may exert their influence through mechanisms other than gene
240 expression, identifying differentially expressed genes within the QTL may be insufficient for ranking
241 causal genes. Here we took an alternative approach and ranked candidates in each QTL based on their
242 predicted association with the mapped traits. To do this, we trained an SVM to classify trait-related genes,
243 and then used the trained SVM to score each positional candidate gene as trait-related or not-trait-
244 related. We defined the training set of trait-related genes for the SVM as those genes that were highly
245 correlated to the measured trait using the gene expression data described above. We calculated the
246 Pearson correlation between the abundance of each transcript, and each physiological trait using rank Z
247 normalized gene expression and traits. For each trait, we defined the training set of trait-related genes
248 as the 500 genes with the largest magnitude Pearson correlation to the trait. We have made these gene
249 lists available as a set of zipped text files in Supplemental File 1.

250

251 **Support Vector Machine classifier training**

252 We trained SVMs to classify genes in each gene list as trait-related using features derived from the
253 Functional Network of Tissues in Mouse [32]. The nodes in this network are genes, and the edges
254 between them are weights between 0 and 1 that predict the likelihood that each pair of genes is annotated
255 to the same Gene Ontology (GO) term or KEGG pathway [30]. Values closer to one indicate more
256 certainty that the genes are more likely to be annotated to the same GO term or KEGG pathway and thus
257 functionally related. The weights were derived using Bayesian integration of data sets from numerous
258 sources of data, including gene expression, protein-protein interaction data, and phenotype annotations
259 [32]. We used the top edges of the mouse lung network downloaded on March 31, 2021, from
260 <http://fntm.princeton.edu>.

261

262 **Application of Support Vector Machine classifiers to identify genes functionally related to traits.**

263 We used SVMs to classify each positional candidate as trait-related or not-trait-related, as described
264 previously [30, 31]. Briefly, the expression-derived gene sets for each lung trait served as the *positive*
265 *labeled set* of genes. We used the R package e1071 [65] to train SVMs to distinguish this set of genes
266 from a balanced set of genes drawn randomly from the remaining genes in the lung network. The
267 randomly selected genes were the *unlabeled set*. We performed this training 100 times, each time with
268 a new set of random unlabeled genes. The SVMs were trained to distinguish positive labeled genes from
269 unlabeled genes using the connection weights to the positive labeled genes. It is expected that positively
270 labeled genes have relatively strong connections to each other because they are functionally related. It
271 is further expected that randomly drawn genes will be unrelated to the trait and to the positive labeled set
272 and will thus have relatively lower connection weights to the positive labeled genes. The SVM learns to
273 distinguish these two groups of genes, and the resulting model can be used to classify genes that have
274 not been seen before based on their connection weights to the positively labeled genes. We initialized
275 each run by tuning the SVM over a series of cost parameters, starting with the sequence 10^{25} to 10^2 by

276 factors of 10, and iteratively narrowing the range until we found a series of eight cost parameters that
277 maximized accuracy. In running each SVM, we used a linear kernel and 10-fold cross-validation.

278 We calculated the area under the receiver operating characteristic curves (AUC) for each set of
279 trait-related genes as follows. We defined labeled positives (LP) as positive labeled genes that were
280 classified by the SVM as trait related. Unlabeled negatives (UN) were unlabeled genes that were
281 classified by the SVM as not trait related. Unlabeled positives (UP) were unlabeled genes that were
282 classified as trait-related, and labeled negatives (LN) were positive labeled genes that were classified as
283 not trait-related. These terms are conceptually like true/false positive and true/false negative scores.
284 However, because unlabeled genes may not be truly unrelated to the trait, we cannot call them true
285 negatives. Instead, we call them *unlabeled*. We generated ROC curves using the *Unlabeled Predicted*
286 *Positive Rate* (UPPR = UP/(UP+UN)), which is akin to the false positive rate, and the labeled positive
287 rate (LPR = LP/(LP+UN)), which is akin to the false negative rate, along a series of SVM scores from the
288 minimum to the maximum. We then calculated the average AUC across all 100 SVMs.

289

290 **Positional Candidate Scoring**

291 After training SVMs for each trait, we scored all positional candidate genes in each QTL, defined as the
292 minimum to the maximum position across a set of overlapping QTLs. Each candidate gene received one
293 score for each trait that mapped to that location. To compare scores across traits, we used the UPPR for
294 each gene at its calculated SVM score. The UPPR varies between 0 and 1, allowing us to compare
295 scores for candidate genes across models. To visually compare across models, we used the
296 $-\log_{10}(\text{UPPR})$ such that genes with very small UPPR (very high confidence) got large positive values. In
297 contrast, the SVM scores cannot be used to compare across models because they are unbounded and
298 vary from model to model. Within each pleiotropic QTL, each gene received a score from each trait that
299 mapped to the QTL.

300

301 **Mouse Genome Build and Database Versions**

302 We used mouse genome build GRCm38 and SNPs and Indels from the Sanger Mouse Genomes Project,
303 version 7, which uses Ensembl version 97 gene models. We also used and cross-referenced candidates
304 with the Mouse Phenome Database GenomeMUSter, the Mouse Genome Informatics databases [66],
305 and Ensembl's Variant Effect Predictor tool.

306

307 **RESULTS**

308 ***Survival and body weight changes***

309 We infected Diversity Outbred mice by aerosol with ~100 *M. tuberculosis* colony forming units in
310 the first two experiments (N=167), and ~25 colony forming units in the subsequent eight experiments
311 (N=683). Infection reduced survival of Diversity Outbred mice compared to identically housed, age-,
312 gender-, and generation-matched uninfected Diversity Outbred mice and to identically housed age- and
313 gender-matched infected C57BL/6J inbred mice (Figure 1A). Approximately one-third of infected Diversity
314 Outbred mice succumbed prior to 60 days (Figure 1A) reflecting early mortality between 20-56 days that
315 peaked at 30 days (Figure 1B). This supersusceptible fraction of the Diversity Outbred population has
316 been named Progressors [24, 57, 60, 67]. Morbidity in all Progressors was due to pulmonary TB,
317 confirmed by histology, recovery of viable *M. tuberculosis* bacilli from the lungs and absence of other
318 diseases. After the first mortality wave subsided, cumulative survival declined slowly to nearly 600 days
319 with no discernable mortality waves (Figure 1A and 1B). This relatively resistant fraction of Diversity
320 Outbred mice has been named Controllers [24, 57, 60, 67]. The eight founder strains survived at least
321 40 days of *M. tuberculosis* infection, without early mortality (Figure 1A).

322 All mice were weighed prior to infection, during infection, and immediately before euthanasia.
323 Non-infected Diversity Outbred mice gained weight until they developed other diseases or were
324 euthanized at the experiment end (Supplemental Figure 1A). Progressors gained weight for 2-3 weeks,
325 and then quickly lost weight (Supplemental Figures 1B). Controllers and C57BL/6J inbred mice gained
326 weight for long and variable durations through about 250 days of infection, and then most but not all
327 slowly lost weight (Supplemental Figures 1C, 1D). We questioned whether pre-infection body weight

328 influenced differential susceptibility. Retrospective analysis identified no significant differences in pre-
329 infection body weights of non-infected Diversity Outbred mice compared to Progressors; and a significant
330 difference (average of 1.75 gm lower) in mean body weights of non-infected Diversity Outbred mice and
331 Progressors compared to Controllers (Supplemental Figure 2A). Whether this is spurious or biologically
332 relevant (i.e., heavier pre-infection body weight partially protects) remains to be determined.
333 Supplemental Figures 2B, 2C, and 2D show correlations between survival and eight clinical indicators of
334 disease. Seven indicators positively correlate with survival, including pre-infection body weight which was
335 weakly positive. Only one indicator, the rate of body weight loss, had negative correlations with survival
336 and the duration of weight loss.

337

338 ***Lung Histology and Automated Image Analysis of Granuloma Necrosis***

339 By eight weeks of *M. tuberculosis* infection, Diversity Outbred mice showed a spectrum of lung
340 lesions visible at low magnification (Figure 2) with variation in severity (minimal to marked); distribution
341 of cellular infiltrates (focal, multifocal, and diffuse); and granuloma content (e.g., necrotizing, and non-
342 necrotizing, shown in Supplemental Figure 3 at higher magnification). Additional lesions included fibrin
343 thrombosis with alveolar septal necrosis; cavities with peripheral fibrosis; foamy and multinucleated
344 macrophages with cholesterol clefts; formation of secondary lymphoid follicles; alveolar septal fibrosis;
345 and intra- and extracellular *M. tuberculosis* bacilli described elsewhere [19, 24, 60, 68-71]. Since
346 granuloma necrosis is a key feature of pulmonary TB in humans, we focused on this, and used our
347 automated image analysis method to quantify the ratio of granuloma necrosis in lung tissue sections [57].

348

349 ***Quantification of lung traits: M. tuberculosis burden and immune responses***

350 We quantified *M. tuberculosis* lung burden by counting colonies from lung tissue homogenates
351 and used the remainder lung homogenates for quantification of lung cytokines and chemokines by ELISA
352 [24, 39]. Most lung traits were significantly higher in mice infected with *M. tuberculosis* compared to non-
353 infected mice (Figures 3A), including neutrophil and monocyte/macrophage chemokines (CXCL1,

354 CXCL2, CXCL5); mediators of innate immunity (S100A8, Tumor Necrosis Factor (TNF), interleukin (IL)-
355 10, matrix metalloproteinase-8 (MMP8); mediators of acquired immunity (interferon-gamma (IFN- γ) and
356 *M. tuberculosis* burden. Pairwise Pearson correlation of all traits in infected mice showed that all the lung
357 traits except IL10 and VEGF positively correlated with each other (Figure 3B). Like previous findings in a
358 small study of Diversity Outbred mice [24], correlations were strongest between *M. tuberculosis* lung
359 burden and mediators of acute neutrophilic inflammation, innate immunity, and extracellular matrix
360 degradation: CXCL1, CXCL2, TNF, and MMP8 with a mean correlation of 0.75.

361

362 ***Overview of genetic mapping and gene prioritization within QTLs.***

363 Figure 5 shows a flow diagram of the types of input data for genetic mapping to identify QTLs,
364 and the subsequent methods of gene prioritization. Briefly, we performed linkage mapping on each trait
365 by regressing each on the additive founder allele dosage at each locus using the R package qtl2 [62].
366 We selected peaks with a permutation-derived significance threshold of 7.62 ($p_{GW} \leq 0.05$) and found
367 seven peaks associated with multiple traits on chromosomes 1, 2, 3, 4, 16, and 17 (Table 1 and Figure
368 4). We observed that correlated traits colocalized to shared QTLs, and had similar patterns of allele
369 effects, so we used a two-step procedure in which we recorded the confidence interval for peaks with a
370 LOD ≥ 7.62 and then looked for peaks of colocalized traits with a LOD ≥ 6.0 ($p_{GW} \leq 0.6$). We reasoned
371 that once we had found the first significant peak for one trait, the threshold for colocalized peaks with the
372 same pattern of founder allele effects should be lower, allowing refinement of the loci.

373

374 ***Chromosome 1: Diversity Outbred Tuberculosis Susceptibility locus 1 (Dots1)***

375 *Dots1* is a new QTL on chromosome 1 with a peak LOD >7.6 ($p_{GW} < 0.05$) at 155.36 M and interval
376 154.25-156.71 Mb shared by two correlated traits, *M. tuberculosis* burden and CXCL1 (Table 1). Two
377 correlated traits (CXCL2 and MMP8) had lower threshold LODs ≥ 6.0 ($p_{GW} \leq 0.6$) mapped to the same
378 position (Figure 4). Notably, these four correlated traits shared patterns of founder allele effects
379 (Supplemental Figure 5), suggesting this QTL contains an important mechanism of genetic regulation for

380 neutrophil-mediated activities, extracellular matrix remodeling, and *M. tuberculosis* growth. To refine the
381 locus, we calculated the first principal component of those four traits and plotted the LOD curve, which
382 also peaked between 154-156 Mb (Figure 6A) and plotted the founder allele effects. A/J, C57BL/6J and
383 WSB/EiJ alleles contributed to higher values of principal component 1 and CAST/EiJ alleles contributed
384 to low allele effects (Figure 6B). We next imputed the founder SNPs onto the Diversity Outbred genomes
385 and performed association mapping in a 10 Mb region around the peak (Figure 6C). Interestingly, the
386 SNPs with highest LOD scores were outside of the peak, and none of the SNPs with the highest LOD
387 scores were missense, stop, or splice site SNPs. This suggested the SNPs in the confidence interval
388 could regulate expression of nearby genes, including some of the 47 protein-coding genes in the interval
389 (Figure 6D and Supplemental File 1). To find and prioritize trait-related gene candidates within *Dots1*, we
390 used the trained SVM model to rank gene candidates based on the strength of their functional relationship
391 in gene expression network modules (Supplemental File 2). *Fam20b* and *Ncf2* ranked highest by
392 functional scoring (Figure 6E). Table 2 summarizes the known annotations, allele effects, founder alleles
393 containing SNPs, and predicted effects of missense SNPs in *Fam20b* and *Ncf2* genes on protein
394 functions from publicly available databases.

395

396 **Chromosome 2: Diversity Outbred Tuberculosis Susceptibility locus 2 (Dots2)**

397 *Dots2* is a new QTL, not shared by correlated traits (Table 1), and has a peak LOD of 7.69 (p_{GW}
398 < 0.05) at 22.43 Mb that was associated with lung CXCL2 protein levels (Figure 4). *Dots2* contains 19
399 protein coding genes (Supplemental File 1). Because this QTL was associated with only 1 trait, gene
400 prioritization by functional scoring was not pursued.

401

402 **Chromosome 3: Diversity Outbred Tuberculosis Susceptibility locus 3 (Dots3)**

403 *Dots3* is not a new QTL (Table 1) and overlaps with *tbs1*, a QTL previously identified by crossing
404 A/Sn and I/St inbred mouse strains [72]. These strains are not founder strains of the Diversity Outbred
405 population. *Dots3* was identified by a single peak with a high LOD of 16.57 at 90.69 Mb and interval

406 90.52-92.02 ($p_{GW} < 10^8$) associated with lung S100A8 (calgranulin A) protein levels (Figure 4 and Figure
407 7A). CAST/EiJ alleles effects were high and PWK/PhJ allele effects were low (Figure 7B). SNPs with the
408 highest LOD scores within the peak are shown (Figure 7C). The interval contains 12 protein coding genes
409 (Supplemental File 1) including the *S100a8* gene (Figure 7D), suggesting that genetic variants which
410 affect *S100a8* transcription regulate S100A8 (calgranulin A) protein levels in *M. tuberculosis* infection.
411 Further, based on based on the strength of the functional relationship in gene expression network
412 modules (Supplemental File 2) the trained SVMs identified *S100a8* as the gene with the highest functional
413 score in *Dots3* (Figure 7E). *Dots3* also contains the gene *S100a9*, which encodes S100A9 (calgranulin
414 B), a protein binding partner of S100A8 (calgranulin A) required to form the heterodimer, calprotectin.
415 Table 2 summarizes the known annotations, allele effects, founder alleles containing SNPs, and
416 predicted effects of missense SNPs in *S100a8* and *S100a9* genes on protein functions from publicly
417 available databases.

418

419 ***Chromosome 4: Diversity Outbred Tuberculosis Susceptibility locus (Dots4)***

420 *Dots4* is new QTL, not shared by correlated traits (Table 1), and has a peak LOD of 7.64 ($p_{GW} <$
421 0.05) at 22.43 Mb and interval 22.18-23.79 Mb associated with lung S100A8 (calgranulin A) protein
422 levels (Figure 4). *Dots4* contains 2 protein coding genes (Supplemental File 1). Because this QTL was
423 associated with only one trait and contained few protein coding genes, prioritization by functional scoring
424 was not pursued.

425

426 ***Chromosome 16: Diversity Outbred Tuberculosis Susceptibility locus (Dots5)***

427 *Dots5* is a new QTL on chromosome 16, shared by three correlated traits: lung *M. tuberculosis*
428 burden (LOD = 8.45, $p_{GW} \leq 0.01$), weight loss, and granuloma necrosis with a peak at 38.3 Mb and
429 interval 33.28-43.28 Mb (Table 1 and Figure 4). We calculated the first principal component of these traits
430 and plotted the LOD curve showing its peak (Figure 8A). The founder allele effects indicate that C57BL/6J
431 alleles contribute to higher values of principal component 1 and that PWK/PhJ and NZO/HILtJ alleles

432 contribute to low effects (Figure 8B). We imputed the founder SNPs onto the Diversity Outbred genomes
433 and performed association mapping around the peak, showing the SNPs with the highest LOD scores
434 (Figure 8C). The SNPs with high LOD scores (Figure 8D) were not missense, stop, or splice site SNPs
435 in the 75 protein coding genes within the interval (Supplemental File 1). By prioritizing genes based on
436 functional relationships in network modules, we identified *Fstl1* and *Itgb5* as functional candidates
437 associated with weight loss, and *Zbtb20* as a functional candidate associated with *M. tuberculosis* burden
438 (Figure 8E, Supplemental File 2). Table 2 summarizes the known annotations, allele effects, founder
439 alleles containing SNPs, and predicted effects of missense SNPs in *Fstl1*, *Itgb5*, and *Zbtb20* genes on
440 protein functions from publicly available databases.

441

442 ***Chromosome 16: Diversity Outbred Tuberculosis Susceptibility locus (Dots6)***

443 *Dots6* is new QTL on chromosome 16 and shared by two correlated traits: *M. tuberculosis* burden
444 and CXCL5 with a peak at 52.23 Mb and interval 37.97-57.67 Mb (Table 1 and Figure 4). The interval
445 contains 101 protein coding genes (Supplemental File 1). Because the LOD score was lower than LOD
446 threshold 7.64 for significance ($p_{GW} < 0.05$), prioritization by functional scoring was not pursued.

447

448 ***Chr 17: Diversity Outbred Tuberculosis Susceptibility locus (Dots7)***

449 *Dots7* on chromosome 17 is not new, overlaps with *sst5* and *sst6*, QTLs that were previously
450 identified by crossing C3HeB/FeJ and C57BL/6J inbred mouse strains [73]. These strains are not founder
451 strains of the Diversity Outbred population. *Dots7* is associated with *M. tuberculosis* burden and the LOD
452 peaks ~20 Mb (Table 1 and Figure 4). The interval contains 198 protein coding genes (Supplemental File
453 1). Because the LOD score was lower than LOD threshold 7.64 for significance ($p_{GW} < 0.05$), prioritization
454 by functional scoring was not pursued.

455

456 ***Chr 17: Diversity Outbred Tuberculosis Susceptibility locus (Dots8)***

457 *Dots8* is not a new QTL and also overlaps with *sst5* and *sst6*, two QTLs that were previously
458 identified by crossing C3HeB/FeJ and C57BL/6J inbred mouse strains [73]. Five traits: lung granuloma
459 necrosis (“Necr Ratio”), weight loss, MMP8, CXCL1, and IL-10 mapped to *Dots8*. Lung granuloma
460 necrosis had the highest LOD score (LOD = 8.12, $p_{GW} \leq 0.02$) at 35.02 Mb and interval 33.94-41.06 Mb
461 Of those five traits, four positively correlated with each other (Figure 3) and had similar patterns of allele
462 effects, while one associated trait, IL-10 had weak correlations and different patterns of founder allele
463 effects.

464 We calculated the first principal component of the correlated traits and again performed QTL
465 mapping. Principal component 1 mapped to a wide interval approximately 30-50 Mb with a peak near 38
466 Mb (Figure 9A). The founder allele effects show PWK/PhJ alleles contribute to high trait values, and
467 NZO/HILtJ and NOD/ShiLtJ alleles contribute to lower values (Figure 9B). We expected to find
468 polymorphisms in the proximal peak of *Dots8* at 34-38 Mb because it contains the mouse
469 histocompatibility-2 (H-2; or Major Histocompatibility Complex-II MHCII). This locus contains many
470 immune response genes known to regulate innate and adaptive immunity and is known to be highly
471 polymorphic. Indeed, the highest SNP association mapping LOD scores were over the mouse H-2 locus,
472 located approximately 36-38 Mb (Figure 9C), and there were 27 SNPs with protein-coding or splice site
473 variation which occurred in 15 genes (Supplemental File 3). Among these were several histocompatibility
474 genes (*H2-M1*, *H2-M5*, *H2-M9*, *H2-M11*) and several tripartite motif (TRIM) family genes (*Trim10*, *Trim26*,
475 *Trim31*, *Trim40*).

476 The genes within the broad interval of the *Dots8* are difficult to summarize and interpret as there
477 were 361 protein-coding genes within the 30-50 Mb locus (Supplemental File 1). We prioritized these
478 positional candidate genes again based on their functional relationships in network modules to the
479 correlated traits (Supplemental File 2). This identified candidates *Ddr1*, *Ier3*, and *Vegfa* associated with
480 CXCL1; and *Zfp318* associated with granuloma necrosis (Figure 9E). Table 2 summarizes the
481 annotations, allele effects, founder alleles containing SNPs, and predicted effects of missense SNPs in
482 *Ddr1*, *Ier3*, *Vegfa*, and *Zfp318* genes on protein functions from publicly available databases.

483

484 **Selected methodological and gene candidate validation.**

485 We performed three different types of validation shown in Supplementary Figure 6. This included
486 (i) survival analysis of Diversity Outbred mice carrying PWK/PhJ alleles at the H-2 locus in *Dots8* on
487 chromosome 17; (ii) quantification of S100A8 protein levels in lungs of *M. tuberculosis* infected PWK/PhJ
488 and CAST/EiJ inbred founder strains; and (iii) infection of gene deficient mice. Notably, infected Diversity
489 Outbred mice carrying at least one copy of the PWK/PhJ allele at the mouse H-2 locus had shorter
490 survival than mice carrying other alleles at the H-2 locus (Supplemental Figure 6A). The lungs of *M.*
491 *tuberculosis* infected CAST/EiJ inbred mice contained significantly higher levels of S100A8 protein
492 (calgranulin A) than PWK/PhJ inbred mice (Supplemental Figure 6B), confirming the founder allele effects
493 on chromosome 3 *Dots3* QTL, and the levels of S100A8 (calgranulin A) appeared unrelated to *M.*
494 *tuberculosis* control (Supplemental Figure 6D). Finally, to test *in vivo* effects of one gene candidate, we
495 selected the candidate with the highest LOD score (*S100a8* in *Dots3* QTL on chromosome 3) and
496 obtained C57BL/6 breeding pairs to generate knockout, heterozygous, and wild-type mice. Genotype-
497 tested littermates with null mutation (“knockout”), heterozygous, and wild-type C57BL/6 *S100a8* alleles
498 were infected with *M. tuberculosis*. The absence of one or both copies of the C57BL/6 *S100a8* allele
499 (which is the reference genotype) had minimal impact on *M. tuberculosis* lung burden (Supplemental
500 Figure 6C) suggesting other mechanisms compensate for its absence on the C57BL/6 background.

501

502 **Discussion**

503 TB remains a major public health concern in the United States and across the globe, with an
504 estimated 2 billion people infected with *M. tuberculosis*; 8-9 million patients diagnosed each year, and 1-
505 1.5 million deaths annually [2]. Fortunately, most humans (~90%) are highly resistant to *M. tuberculosis*
506 and clear or control infection [11, 74]. In susceptible adults, active pulmonary TB develops a few years
507 following exposure and tends to occur in young to middle-aged adults in the prime years of their lives
508 [75]. The disease is usually restricted to the lungs and is characterized by granuloma necrosis and

509 cavitation, neutrophilic infiltration, and cachexia [76, 77]. The genetic basis of pulmonary TB is complex
510 and not attributable to single-gene defects that cause severe immune deficiency (i.e., Mendelian
511 susceptibility to mycobacterial disease does not explain pulmonary TB) [15, 78-83]. Although genome-
512 wide association studies have identified loci, gene candidates, and SNPs associated with increased or
513 decreased odds ratios for pulmonary TB, only a few (e.g., *Ipr1/SP110b* and *HLA* variants/*I-A Major*
514 *Histocompatibility genes*) have been validated [16, 84-90]. This has led investigators to seek alternative
515 experimental mouse models such as Diversity Outbred mice and Collaborative Cross recombinant inbred
516 strains to examine effects of genetics on host responses to *M. tuberculosis* [24-26, 38].

517 An advantage of the Diversity Outbred mouse population is that infection with *M. tuberculosis* induces
518 phenotypes that are rare in common laboratory inbred strains of mice [15-17]. Further, a growing body of
519 evidence shows similarities in *M. tuberculosis*-infected Diversity Outbred mice and humans in
520 biomarkers, gene expression signatures, and BCG vaccination [38, 39, 67, 68, 91]. The phenotypic
521 similarities suggest that humans and Diversity Outbred mice may share underlying genetic pathways of
522 immunity and disease. And, because SNP variants in the Diversity Outbred mouse genomes are dense,
523 with balanced allele frequencies, any gene that plays a role in disease is theoretically detectable [92].
524 This eliminates a problem common to human genetic studies where under-represented alleles cannot be
525 confidently associated with disease phenotypes because they are low-frequency genetic events.

526 We performed genetic mapping in *M. tuberculosis*-infected Diversity Outbred mice and used
527 orthogonal methods to rationally select candidate genes. We first used DOQTL mapping, which relies
528 entirely on phenotypic and genetic variation, to find eight QTLs on six different chromosomes named
529 *Dots1* through *Dots8*. To refine loci, we then subjected the QTLs on chromosomes 1, 16, and 17 (*Dots1*,
530 *Dots5*, and *Dots 8*) by mapping the first principal component of the correlated traits with similar patterns
531 of allele effects that colocalized to the same interval. Finally, we applied a gene-based machine-learning
532 SVM to identify and rank gene candidates based on functional scores. The sequential methods narrowed
533 the candidate gene list to eleven polymorphic, protein coding genes. Finally, the SNPs were critically

534 examined using publicly available databases to find four candidates (*S100a8*, *Itgb5*, *Fstl1*, *Zfp318*) where
535 missense SNPs are predicted to have deleterious effects on protein function.

536 All eleven candidates have roles in infection, inflammation, cell migration, extracellular matrix
537 remodeling, or intracellular signaling. Of those, only one (mouse *Ncf2* in *Dots1* on chromosome 1) has a
538 human homologue where a single SNP (G nucleotide in human NCF2 rs10911362) may provide a
539 protective effect it lowered the odds ratio of pulmonary TB [93]. Absence of *Ncf2* on the C57BL/6 inbred
540 mice this temporarily impairs resistance to *M. tuberculosis* infection by abrogating superoxide production,
541 but the defect does not affect overall survival due to compensation by T cell mediated immunity [94].
542 Experimental validation of mouse *Ncf2* and human NCF2 polymorphisms remains to be confirmed.

543 We identified *Fam20b* in *Dots1* QTL on chromosome 1. The gene encodes a xylosylkinase that
544 functions in glycosaminoglycan synthesis to produce extracellular matrix components in tissues.
545 Deficiencies are embryologically lethal or cause cranioskeletal malformations [44, 45, 95, 96]. A
546 functionally homologous enzyme phosphorylates cadherins [97] which regulate immune cell migration
547 [98] by interacting with extracellular matrix components, and since cell migration is required to form
548 mycobacterial granulomas, *Fam20b* polymorphisms may alter host susceptibility to *M. tuberculosis* by
549 changing extracellular matrix.

550 We identified *S100a8* and *S100a9* in *Dots3* QTL on chromosome 3, which encode S100A8
551 (calgranulin A) and S100A9 (calgranulin B). The proteins form monomers, homodimers, heterodimers,
552 and multimers in inflammation, host defense, and nociception [99-102]. Some forms activate Toll-Like
553 receptor 4 signaling; some activate the receptor for advanced glycation end-products; and some
554 sequester calcium, zinc, and manganese metal ions [99, 103, 104]. In pulmonary TB, S100A9 contributes
555 to neutrophil localization to granulomas, and both S100A8 and S100A9 are protein biomarkers of TB-
556 related lung damage [38, 39, 104-107]. Interestingly, 4 polymorphisms in *S100a8* were predicted to have
557 deleterious effects on function but the lack of S100a8 did not change the ability of C57BL/6 inbred mice
558 to restrict *M. tuberculosis* growth. Further investigation would be required to determine the effects on
559 other host outcomes.

560 We identified *Itgb5* in *Dots5* QTL on chromosome 16 as a gene candidate. *Itgb5* encodes the beta
561 5 (β 5) integrin subunit which dimerizes with the alpha v subunit to mediate cell adhesion and signaling
562 by binding to fibronectin and vitronectin [41]. Notably, the β 5 subunit is on the surface of cancer cells,
563 and normal epithelial cells and activated endothelial cells but not on lymphoid or myeloid cells [41, 108-
564 114]. To our knowledge, neither the mouse nor human gene, nor subunit β 5, nor the $\alpha v \beta 5$ integrin
565 heterodimer have been deeply investigated in pulmonary TB.

566 We identified *Fstl1* in *Dots5* QTL on chromosome 16. The primary transcript encodes microRNA
567 (miR)-198. The product is a secreted glycoprotein, FSTL1 with activities in angiogenesis, cell
568 proliferation, differentiation, embryogenesis, metastasis, and wound healing; specifically reducing
569 inflammation and fibrosis in cardiovascular disease [43, 115-118]. Notably, *Fstl1* affects survival of *M.*
570 *tuberculosis*-infected macrophages [34, 35, 119]. Given the central role of macrophages, inflammation,
571 and fibrosis in *M. tuberculosis* infection, understanding how *Fstl1* polymorphisms and FSTL1 function *in*
572 *vivo* may inform TB pathogenesis, and possibly targets for host-directed therapy.

573 We identified *Zbtb20* in *Dots5* QTL on chromosome 16. The gene encodes a transcriptional
574 repressor involved in glucose homeostasis; growth; hematopoiesis; innate immunity; neurogenesis; and
575 B cell development and long-term survival of plasma cells [46-49, 120-124]. Natural mutations occur in
576 humans with Primrose Syndrome, although immune deficiencies are not reported [125]. To our
577 knowledge, there are no studies on *Zbtb20* and *M. tuberculosis* infection or pulmonary TB. However, in
578 *Listeria monocytogenes* infection, *Zbtb20*-deficiency improved CD8 T cell memory functions due to
579 efficient use of diverse fuel sources [49]. Whether the same is true in pulmonary TB is unknown.

580 We identified *Ddr1* in *Dots8* QTL on chromosome 17. *Ddr1* encodes for the discoidin domain
581 receptor 1 (DDR1), which interacts with collagen [42]. Initial studies suggested DDR1 function was
582 restricted to epithelial cells; however, recent work shows expression on solid tumors, metastatic cells,
583 and mouse histiocytic cancer cell lines, J774 and Raw264.7 [126-132]. DDR1 has additional roles in
584 demyelination, fibrosis, vitiligo, and wound healing, and it is also a promising target for anti-fibrotic therapy

585 [133-137]. Whether *Ddr1* (mouse) or DDR1 (human) gene polymorphisms contribute to pulmonary TB,
586 or whether it could be a target for anti-fibrotic therapy in TB are areas open for investigation.

587 We identified the immediate early response gene, *Ier3* in *Dots8* QTL on chromosome 17. *Ier3*
588 transcription is triggered by cytokines, hormones, DNA damage, and infections. The protein, IER3,
589 regulates apoptosis, DNA repair, differentiation, and proliferation by interfering with NF- κ B, MAPK/ERK
590 and PI3K/Akt signaling pathways [50-52, 138-141]. Mice lacking *Ier3* are more susceptible to *Leishmania*
591 [142], an intracellular pathogen that shares some similar immune responses profiles with those induced
592 by *M. tuberculosis* but we did not find studies showing that mutated *Ier3* also increases susceptibility to
593 *M. tuberculosis*. One *in vitro* study of human macrophages, however, had high levels of IER3 mRNA
594 following infection with a hypervirulent strain of *M. tuberculosis* [143] indicating the transcriptional
595 pathway is triggered.

596 We identified *Vegfa* in *Dots8* QTL on chromosome 17. Mouse *Vegfa* and human VEGFA, encode
597 for a heparin-binding protein and essential growth factor that induces proliferation, migration, and
598 permeability changes in vascular endothelial cells by binding VEGFR1 and VEGFR2 [144-147]. Roles for
599 VEGF in pathogenesis and diagnostics for extrapulmonary TB, cavitary TB, and active TB have been
600 published [148-150]. Myeloid-specific gene deletion of *Vegfa* extended survival of C57BL/6J inbred mice
601 infected with *M. tuberculosis* [151], highly noteworthy because very few gene deletions improve survival.
602 Whether *Vegfa* or VEGFA polymorphisms have the same effect is unknown.

603 Lastly, we identified *Zfp318* in *Dots8* QTL on chromosome 17. The gene encodes the transcription
604 factor, zinc finger protein 318 and it is expressed in testes, hematopoietic, and lymph nodes [152]. In B
605 cells, the protein represses transcription required for class switching, helping to maintain B cell anergy
606 and prevent autoimmunity [153-155]. Database and literature searches identified no publications on
607 mouse *Zpf318* or human ZPF318 in infectious diseases.

608 When we compared genetic mapping results from Diversity Outbred mice to results from colleagues
609 using Collaborative Cross inbred strains [26], QTLs and gene candidates did not overlap although we
610 measured a few of the same traits by standard laboratory methods (e.g., body weight changes, lung *M.*

611 *tuberculosis* burden, and lung CXCL1 by immunoassays). This suggests that phenotype-genotype
612 relationships in the Collaborative Cross strains may be fundamentally different than Diversity Outbred
613 mouse population (despite sharing the same eight inbred founder strains), possibly because of high levels
614 of heterozygosity in the Diversity Outbred population. Other reasons could be differences in routes of
615 infection that change the host cell types first encountering *M. tuberculosis* bacilli which alters antigen
616 presentation, T-cell, and B-cell priming. Here, we modeled natural aerosol exposure by delivering a low
617 dose of approximately 20-100 bacilli to the lungs of Diversity Outbred mice in nebulizer-delivered aerosol
618 mist, and then focused on quantification of lung disease. In contrast, Smith *et al* [26] took a different
619 approach by using intravenous infection with 1×10^6 bacilli to take advantage of their rich library of
620 transposon mutants, allowing detailed assessment of pathogen-associated QTLs. As the intravenous
621 route of infection favors rapid induction of acquired immunity by delivering bacilli directly to lymphoid
622 organs (i.e., spleen, thoracic, and abdominal lymph nodes by portal and systemic circulation), this
623 approach maximized identification of unique Host-Interacting-with Pathogen QTLs and resulted in a
624 prioritized list of candidate genes involved in immunity.

625 Overall, by using a systems genetics approach focused on the lungs, we multiple new and existing
626 QTLs, and 11 candidate genes. Of those, gene products for five (*Ncf2*, *Fstl1*, *Zbtb20* *Vegfa*, *Zfp318*) have
627 known roles in recruitment, activation, or regulation of effector functions of immune cells (e.g.,
628 neutrophils, monocytes, macrophages and CD8 T cells). The gene products for three candidates
629 (*Fam20b*, *Itgb5*, *Ddr1*) have known roles in epithelial cell, endothelial cell, and (possibly) macrophage
630 adhesion to extracellular matrix glycoproteins or are involved in remodeling of extracellular matrix. The
631 gene products for two candidates (*S100a8* and *S100a9*) have complex and context-dependent roles in
632 innate immune response signaling and in host defenses. Finally, the gene product of one candidate (*ler3*)
633 controls early stress responses of cells, including cell survival and death pathways. Ten of the eleven
634 candidates have annotated polymorphisms; six have missense SNPs in protein coding regions; and the
635 SNPs in four candidates (*S100a8*, *Itgb5*, *Fstl1*, and *Zfp318*) are predicted to have deleterious
636 consequences on protein functions. Together, these results yield a short list of candidates that may be

637 major regulators of host necrotizing and inflammatory responses during *M. tuberculosis* infection and
638 pulmonary TB disease progression. Future studies will focus on testing effects of these gene candidates
639 and polymorphisms *in vivo* and identification of pathogenic molecular and cellular mechanisms.

640

641 **Acknowledgements**

642 We thank Ms. Julie Tzipori, Mr. Curtis Rich, Mr. Donald Girouard, and Dr. Sam Telford III for study support
643 at the New England Regional Biosafety Laboratory at Tufts University Cummings School of Veterinary
644 Medicine, North Grafton, MA. NIH NIAID UC6A1066843 supported construction of the New England
645 Regional Biosafety Laboratory. Ms. Frances Brown, Ms. Linda Wrijil, Ms. Sarah Ducat, Ms. Gina Scarglia,
646 and Dr Amanda Martinot provided histology services at Tufts University's Cummings School of Veterinary
647 Medicine. Whole slide imaging was performed by the Digital Histology Shared Resource at Vanderbilt
648 University Medical Center. The following reagents were obtained through BEI Resources, supported by
649 NIH NIAID: ESAT-6, Recombinant Protein Reference Standard, NR-49424; CFP-10, Recombinant
650 Protein Reference Standard, NR49425; Plasmid pMRLB.7 Containing Gene Rv3875 (Protein ESAT-6)
651 from *Mycobacterium tuberculosis*, NR-50170; Plasmid pMRLB.46 Containing Gene Rv3874 (Protein
652 Cfp10) from *Mycobacterium tuberculosis*, NR-13297; *Mycobacterium tuberculosis*, Strain H37Rv, Culture
653 Filtrate Proteins, NR-14825; and *Mycobacterium tuberculosis*, Strain H37Rv, Cell Wall Fraction, NR-
654 14828. All microarray protocols were carried out by the Boston University Microarray and Sequencing
655 Resource (BUMSR) core facility, and we thank Mr. Eduard Drzik of the BUMSR for initial microarray
656 analyses. The following individuals are thanked for their technical expertise with *in vitro* and *in vivo*
657 experiments: Ms. Victoria Mello at Tufts Cummings School of Veterinary Medicine, North Grafton, MA;
658 Mr. Austin Hossfeld at The Ohio State University, Columbus, OH; and Dr. Joanne Turner at Texas
659 Biomedical Research Institute, San Antonio, TX.

660

661 **Funding**

662 BUMSR and CTSA receive support from NIH UL1TR001430. The experiments and analyses were
663 supported by funding from NIH R21 AI115038 (GB); NIH R01 HL145411 (GB); the American Lung
664 Association Biomedical Research Grant RG-349504 (GB); Tufts University's Cummings School of
665 Veterinary Medicine Summer Research Program (AS). The funders had no role in study design, data
666 collection and analysis, decision to publish, or preparation of the manuscript.

667 **References**

- 669 1. Organization, W.H. *14.9 million excess deaths associated with the COVID-19 pandemic in 2020*
670 *and 2021*. 2022 5/5/2022 5/9/2022]; Available from: <https://www.who.int/news-room/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021>.
- 671 2. Organization, W.H., *Global tuberculosis report 2021*. 2021, World Health Organization: Geneva,
672 Switzerland. p. 57.
- 673 3. WHO, *Global Tuberculosis Report: Multidrug- / rifampicin-resistant TB (MDR/RR-TB):Update*
674 2017. 2017.
- 675 4. WHO, *Global Tuberculosis Report*. 2013.
- 676 5. Soleimanpour, S., et al., *A century of attempts to develop an effective tuberculosis vaccine: Why*
677 *they failed?* Int Immunopharmacol, 2022. **109**: p. 108791.
- 678 6. Heidary, M., et al., *Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment*.
679 Eur J Microbiol Immunol (Bp), 2022.
- 680 7. Kassa, G.M., et al., *Predictors of mortality among multidrug-resistant tuberculosis patients in*
681 *central Ethiopia: a retrospective follow-up study*. Epidemiol Infect, 2020. **148**: p. e258.
- 682 8. Tiemersma, E.W., et al., *Natural history of tuberculosis: duration and fatality of untreated*
683 *pulmonary tuberculosis in HIV negative patients: a systematic review*. PLoS One, 2011. **6**(4): p.
684 e17601.
- 685 9. Vilaplana, C. and P.J. Cardona, *The lack of a big picture in tuberculosis: the clinical point of view,*
686 *the problems of experimental modeling and immunomodulation. The factors we should consider*
687 *when designing novel treatment strategies*. Front Microbiol, 2014. **5**: p. 55.
- 688 10. Achkar, J.M. and E.R. Jenny-Avital, *Incipient and subclinical tuberculosis: defining early disease*
689 *states in the context of host immune response*. J Infect Dis, 2011. **204 Suppl 4**: p. S1179-86.
- 690 11. Verrall, A.J., et al., *Early clearance of Mycobacterium tuberculosis: a new frontier in prevention*.
691 Immunology, 2014. **141**(4): p. 506-13.
- 692 12. Flynn, J.L. and J. Chan, *Immunology of tuberculosis*. Annual Review of Immunology, 2001. **19**: p.
693 93-129.
- 694 13. Hunter, R.L., C. Jagannath, and J.K. Actor, *Pathology of postprimary tuberculosis in humans and*
695 *mice: contradiction of long-held beliefs*. Tuberculosis, 2007. **87**(4): p. 267-78.
- 696 14. Azad, A.K., W. Sadee, and L.S. Schlesinger, *Innate immune gene polymorphisms in tuberculosis*.
697 Infect Immun, 2012. **80**(10): p. 3343-59.
- 698 15. Gibbs, K.D., B.H. Schott, and D.C. Ko, *The Awesome Power of Human Genetics of Infectious*
699 *Disease*. Annu Rev Genet, 2022.
- 700 16. Medhasi, S. and N. Chantratita, *Human Leukocyte Antigen (HLA) System: Genetics and*
701 *Association with Bacterial and Viral Infections*. J Immunol Res, 2022. **2022**: p. 9710376.
- 702 17. Varshney, D., et al., *Systematic review and meta-analysis of human Toll-like receptors genetic*
703 *polymorphisms for susceptibility to tuberculosis infection*. Cytokine, 2022. **152**: p. 155791.
- 704 18. Williams, A. and I.M. Orme, *Animal Models of Tuberculosis: An Overview*. Microbiol Spectr, 2016.
705 **4**(4).
- 706 19. Kramnik, I. and G. Beamer, *Mouse models of human TB pathology: roles in the analysis of*
707 *necrosis and the development of host-directed therapies*. Semin Immunopathol, 2016. **38**(2): p.
708 221-37.
- 709 20. Clark, S., Y. Hall, and A. Williams, *Animal models of tuberculosis: Guinea pigs*. Cold Spring Harb
710 Perspect Med, 2015. **5**(5): p. a018572.
- 711 21. Scanga, C.A. and J.L. Flynn, *Modeling tuberculosis in nonhuman primates*. Cold Spring Harb
712 Perspect Med, 2014. **4**(12): p. a018564.
- 713 22. Dharmadhikari, A.S. and E.A. Nardell, *What animal models teach humans about tuberculosis*.
714 American journal of respiratory cell and molecular biology, 2008. **39**(5): p. 503-8.
- 715 23. Helke, K.L., J.L. Mankowski, and Y.C. Manabe, *Animal models of cavitation in pulmonary*
716 *tuberculosis*. Tuberculosis, 2006. **86**(5): p. 337-48.

718 24. Niazi, M.K., et al., *Lung necrosis and neutrophils reflect common pathways of susceptibility to*
719 *Mycobacterium tuberculosis in genetically diverse, immune-competent mice*. *Dis Model Mech*,
720 2015. **8**(9): p. 1141-53.

721 25. Smith, C., et al., *Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled*
722 *by Host Genotype*. *mBio*, 2016. **7**(5): p. e01516.

723 26. Smith, C.M., et al., *Host-pathogen genetic interactions underlie tuberculosis susceptibility in*
724 *genetically diverse mice*. *Elife*, 2022. **11**.

725 27. Churchill, G.A., et al., *The Diversity Outbred mouse population*. *Mamm Genome*, 2012. **23**(9-10):
726 p. 713-8.

727 28. Tabangin, M.E., J.G. Woo, and L.J. Martin, *The effect of minor allele frequency on the likelihood*
728 *of obtaining false positives*. *BMC Proc*, 2009. **3 Suppl 7**(Suppl 7): p. S41.

729 29. Gatti, D.M., et al., *Quantitative trait locus mapping methods for diversity outbred mice*. *G3*
730 (Bethesda), 2014. **4**(9): p. 1623-33.

731 30. Guan, Y., et al., *Functional genomics complements quantitative genetics in identifying disease-*
732 *gene associations*. *PLoS Comput Biol*, 2010. **6**(11): p. e1000991.

733 31. Tyler, A.L., et al., *Network-Based Functional Prediction Augments Genetic Association To Predict*
734 *Candidate Genes for Histamine Hypersensitivity in Mice*. *G3 (Bethesda)*, 2019. **9**(12): p. 4223-
735 4233.

736 32. Goya, J., et al., *FNTM: a server for predicting functional networks of tissues in mouse*. *Nucleic*
737 *Acids Res*, 2015. **43**(W1): p. W182-7.

738 33. Crouser, E.D., et al., *A Novel In Vitro Human Granuloma Model of Sarcoidosis and Latent*
739 *Tuberculosis Infection*. *Am J Respir Cell Mol Biol*, 2017. **57**(4): p. 487-498.

740 34. Zhang, Z.M., et al., *TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and*
741 *inflammatory responses in Mycobacterium tuberculosis-infected macrophages*. *Exp Cell Res*,
742 2017. **352**(2): p. 313-321.

743 35. Deng, Q., et al., *Circ_0001490/miR-579-3p/FSTL1 axis modulates the survival of mycobacteria*
744 *and the viability, apoptosis and inflammatory response in Mycobacterium tuberculosis-infected*
745 *macrophages*. *Tuberculosis (Edinb)*, 2021. **131**: p. 102123.

746 36. Duan, X.Y., et al., *Baicalin attenuates LPS-induced alveolar type II epithelial cell A549 injury by*
747 *attenuation of the FSTL1 signaling pathway via increasing miR-200b-3p expression*. *Innate*
748 *Immun*, 2021. **27**(4): p. 294-312.

749 37. Henkel, M., et al., *Regulation of Pulmonary Bacterial Immunity by Follistatin-Like Protein 1*. *Infect*
750 *Immun*, 2020. **89**(1).

751 38. Gopal, R., et al., *S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during*
752 *tuberculosis*. *Am J Respir Crit Care Med*, 2013. **188**(9): p. 1137-46.

753 39. Koyuncu, D., et al., *CXCL1: A new diagnostic biomarker for human tuberculosis discovered using*
754 *Diversity Outbred mice*. *PLoS Pathog*, 2021. **17**(8): p. e1009773.

755 40. Qiu, J., et al., *ZBTB20-mediated titanium particle-induced peri-implant osteolysis by promoting*
756 *macrophage inflammatory responses*. *Biomater Sci*, 2020. **8**(11): p. 3147-3163.

757 41. Pasqualini, R., et al., *A study of the structure, function and distribution of beta 5 integrins using*
758 *novel anti-beta 5 monoclonal antibodies*. *J Cell Sci*, 1993. **105 (Pt 1)**: p. 101-11.

759 42. Vogel, W., *Discoidin domain receptors: structural relations and functional implications*. *The*
760 *FASEB journal*, 1999. **13**(9001): p. S77-S82.

761 43. Mattiotti, A., et al., *Follistatin-like 1 in development and human diseases*. *Cell Mol Life Sci*, 2018.
762 **75**(13): p. 2339-2354.

763 44. Kuroda, Y., et al., *A novel gene (FAM20B encoding glycosaminoglycan xylosylkinase) for*
764 *neonatal short limb dysplasia resembling Desbuquois dysplasia*. *Clin Genet*, 2019. **95**(6): p. 713-
765 717.

766 45. Koike, T., et al., *FAM20B is a kinase that phosphorylates xylose in the glycosaminoglycan-protein*
767 *linkage region*. *Biochem J*, 2009. **421**(2): p. 157-62.

768 46. Zhu, C., et al., *Regulation of the Development and Function of B Cells by ZBTB Transcription*
769 *Factors*. Front Immunol, 2018. **9**: p. 580.

770 47. Sutherland, A.P., et al., *Zinc finger protein Zbtb20 is essential for postnatal survival and glucose*
771 *homeostasis*. Molecular and cellular biology, 2009. **29**(10): p. 2804-2815.

772 48. Lightman, S.M., A. Utley, and K.P. Lee, *Survival of Long-Lived Plasma Cells (LLPC): Piecing*
773 *Together the Puzzle*. Front Immunol, 2019. **10**: p. 965.

774 49. Sun, Y., et al., *Zbtb20 Restrains CD8 T Cell Immunometabolism and Restricts Memory*
775 *Differentiation and Antitumor Immunity*. J Immunol, 2020. **205**(10): p. 2649-2666.

776 50. Schilling, D., M.R. Pittelkow, and R. Kumar, *IEX-1, an immediate early gene, increases the rate*
777 *of apoptosis in keratinocytes*. Oncogene, 2001. **20**(55): p. 7992-7997.

778 51. Im, H.-J., M.R. Pittelkow, and R. Kumar, *Divergent Regulation of the Growth-promoting Gene IEX-*
779 *1 by the p53 Tumor Suppressor and Sp1*. Journal of Biological Chemistry, 2002. **277**(17): p.
780 14612-14621.

781 52. Arlt, A. and H. Schäfer, *Role of the immediate early response 3 (IER3) gene in cellular stress*
782 *response, inflammation and tumorigenesis*. Eur J Cell Biol, 2011. **90**(6-7): p. 545-52.

783 53. Harrison, D.E., et al., *Genetically diverse mice are novel and valuable models of age-associated*
784 *susceptibility to Mycobacterium tuberculosis*. Immun Ageing, 2014. **11**(1): p. 24.

785 54. Cykota, J.C., et al., *IL-10 inhibits mature fibrotic granuloma formation during Mycobacterium*
786 *tuberculosis infection*. J Immunol, 2013. **190**(6): p. 2778-90.

787 55. Vesosky, B., et al., *CCL5 participates in early protection against Mycobacterium tuberculosis*.
788 *Journal of Leukocyte Biology*, 2010. **87**(6): p. 1153-65.

789 56. Ullman-Cullere, M.H. and C.J. Foltz, *Body condition scoring: a rapid and accurate method for*
790 *assessing health status in mice*. Lab Anim Sci, 1999. **49**(3): p. 319-23.

791 57. Tavolara, T.E., et al., *Automatic discovery of clinically interpretable imaging biomarkers for*
792 *Mycobacterium tuberculosis supersusceptibility using deep learning*. EBioMedicine, 2020. **62**: p.
793 103094.

794 58. Beamer, G.L., et al., *Peripheral blood gamma interferon release assays predict lung responses*
795 *and Mycobacterium tuberculosis disease outcome in mice*. Clinical and Vaccine Immunology,
796 2008. **15**(3): p. 474-83.

797 59. Keane, T.M., et al., *Mouse genomic variation and its effect on phenotypes and gene regulation*.
798 *Nature*, 2011. **477**(7364): p. 289-94.

799 60. Tavolara, T.E., et al., *Deep learning predicts gene expression as an intermediate data modality*
800 *to identify susceptibility patterns in Mycobacterium tuberculosis infected Diversity Outbred mice*.
801 *EBioMedicine*, 2021. **67**: p. 103388.

802 61. Morgan, A.P., et al., *The Mouse Universal Genotyping Array: From Substrains to Subspecies*. G3
803 (Bethesda), 2015. **6**(2): p. 263-79.

804 62. Broman, K.W., et al., *R/qtl2: Software for Mapping Quantitative Trait Loci with High-Dimensional*
805 *Data and Multiparent Populations*. Genetics, 2019. **211**(2): p. 495-502.

806 63. Cheng, R., et al., *QTLRel: an R package for genome-wide association studies in which*
807 *relatedness is a concern*. BMC Genet, 2011. **12**: p. 66.

808 64. Van Ooijen, J.W., *LOD significance thresholds for QTL analysis in experimental populations of*
809 *diploid species*. Heredity (Edinb), 1999. **83** (Pt 5): p. 613-24.

810 65. David Meyer, E.D., Kurt Hornik, Andreas Weingessel and Friedrich Leisch, *e1071: Misc Functions*
811 *of the Department of Statistics, Probability Theory Group (Formerly: E1071)*, TU Wien. 2021. p.
812 *R package*.

813 66. Blake, J.A., et al., *Mouse Genome Database (MGD): Knowledgebase for mouse-human*
814 *comparative biology*. Nucleic Acids Res, 2021. **49**(D1): p. D981-D987.

815 67. Ahmed, M., et al., *Immune correlates of tuberculosis disease and risk translate across species*.
816 *Sci Transl Med*, 2020. **12**(528).

817 68. Kurtz, S.L., et al., *The Diversity Outbred Mouse Population Is an Improved Animal Model of*
818 *Vaccination against Tuberculosis That Reflects Heterogeneity of Protection*. mSphere, 2020. **5**(2).

819 69. Kus, P., M.N. Gurcan, and G. Beamer, *Automatic Detection of Granuloma Necrosis in Pulmonary*
820 *Tuberculosis Using a Two-Phase Algorithm: 2D-TB*. *Microorganisms*, 2019. **7**(12).

821 70. Niazi, M.K.K., G. Beamer, and M.N. Gurcan, *An application of transfer learning to neutrophil*
822 *cluster detection for tuberculosis: efficient implementation with nonmetric multidimensional*
823 *scaling and sampling*. *SPIE Medical Imaging*. Vol. 10581. 2018: SPIE.

824 71. Niazi, M.K.K., G. Beamer, and M.N. Gurcan, *A computational framework to detect normal and*
825 *tuberculosis infected lung from H and E-stained whole slide images*. *SPIE Medical Imaging*. Vol.
826 10140. 2017: SPIE.

827 72. Sanchez, F., et al., *Multigenic control of disease severity after virulent *Mycobacterium**
828 *tuberculosis infection in mice*. *Infect Immun*, 2003. **71**(1): p. 126-31.

829 73. Yan, B.S., et al., *Genetic architecture of tuberculosis resistance in a mouse model of infection*.
830 *Genes and Immunity*, 2006. **7**(3): p. 201-10.

831 74. Dodd, C.E. and L.S. Schlesinger, *New concepts in understanding latent tuberculosis*. *Curr Opin*
832 *Infect Dis*, 2017. **30**(3): p. 316-321.

833 75. Behr, M.A., P.H. Edelstein, and L. Ramakrishnan, *Revisiting the timetable of tuberculosis*. *Bmj*,
834 2018. **362**: p. k2738.

835 76. Loddenkemper, R., M. Lipman, and A. Zumla, *Clinical Aspects of Adult Tuberculosis*. *Cold Spring*
836 *Harb Perspect Med*, 2015. **6**(1): p. a017848.

837 77. Hunter, R.L., et al., *Pathogenesis of post primary tuberculosis: immunity and hypersensitivity in*
838 *the development of cavities*. *Ann Clin Lab Sci*, 2014. **44**(4): p. 365-87.

839 78. Naranbhai, V., *The Role of Host Genetics (and Genomics) in Tuberculosis*. *Microbiol Spectr*,
840 2016. **4**(5).

841 79. Abel, L., et al., *Human genetics of tuberculosis: a long and winding road*. *Philos Trans R Soc Lond*
842 *B Biol Sci*, 2014. **369**(1645): p. 20130428.

843 80. Kondratieva, E., et al., *Host genetics in granuloma formation: human-like lung pathology in mice*
844 *with reciprocal genetic susceptibility to *M. tuberculosis* and *M. avium**. *PLoS One*, 2010. **5**(5): p.
845 e10515.

846 81. Bustamante, J., et al., *Mendelian susceptibility to mycobacterial disease: genetic, immunological,*
847 *and clinical features of inborn errors of IFN-gamma immunity*. *Semin Immunol*, 2014. **26**(6): p.
848 454-70.

849 82. Qu, H.Q., S.P. Fisher-Hoch, and J.B. McCormick, *Molecular immunity to mycobacteria:*
850 *knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to*
851 *mycobacterial diseases*. *Int J Infect Dis*, 2011. **15**(5): p. e305-13.

852 83. Cottle, L.E., *Mendelian susceptibility to mycobacterial disease*. *Clin Genet*, 2011. **79**(1): p. 17-22.

853 84. Kramnik, I., *Genetic dissection of host resistance to *Mycobacterium tuberculosis*: the *sst1* locus*
854 *and the *Ipr1* gene*. *Curr Top Microbiol Immunol*, 2008. **321**: p. 123-48.

855 85. Tosh, K., et al., *Variants in the *SP110* gene are associated with genetic susceptibility to*
856 *tuberculosis in West Africa*. *Proc Natl Acad Sci U S A*, 2006. **103**(27): p. 10364-10368.

857 86. Pan, H., et al., **Ipr1* gene mediates innate immunity to tuberculosis*. *Nature*, 2005. **434**(7034): p.
858 767-72.

859 87. Kramnik, I., P. Demant, and B.B. Bloom, *Susceptibility to tuberculosis as a complex genetic trait:*
860 *analysis using recombinant congenic strains of mice*. *Novartis Foundation symposium*, 1998. **217**:
861 p. 120-31; discussion 132-7.

862 88. Apt, A.S., et al., *Distinct H-2 complex control of mortality, and immune responses to tuberculosis*
863 *infection in virgin and BCG-vaccinated mice*. *Clinical and experimental immunology*, 1993. **94**(2):
864 p. 322-9.

865 89. Barrera, L.F., et al., *I-A beta gene expression regulation in macrophages derived from mice*
866 *susceptible or resistant to infection with *M. bovis* BCG*. *Mol Immunol*, 1997. **34**(4): p. 343-55.

867 90. Logunova, N., et al., *The QTL within the H2 Complex Involved in the Control of Tuberculosis*
868 *Infection in Mice Is the Classical Class II H2-Ab1 Gene*. *PLoS Genet*, 2015. **11**(11): p. e1005672.

869 91. Scott, N.R., et al., *S100A8/A9 regulates CD11b expression and neutrophil recruitment during*
870 *chronic tuberculosis*. *J Clin Invest*, 2020. **130**(6): p. 3098-3112.

871 92. Yang, H., et al., *On the subspecific origin of the laboratory mouse*. *Nat Genet*, 2007. **39**(9): p.
872 1100-7.

873 93. Jiao, L., et al., *A Novel Genetic Variation in NCF2, the Core Component of NADPH Oxidase,*
874 *Contributes to the Susceptibility of Tuberculosis in Western Chinese Han Population*. *DNA Cell*
875 *Biol*, 2020. **39**(1): p. 57-62.

876 94. Cooper, A.M., et al., *Transient loss of resistance to pulmonary tuberculosis in p47(phox-/-) mice*.
877 *Infect Immun*, 2000. **68**(3): p. 1231-4.

878 95. Wu, J., et al., *FAM20B-catalyzed glycosaminoglycans control murine tooth number by restricting*
879 *FGFR2b signaling*. *BMC Biol*, 2020. **18**(1): p. 87.

880 96. Saiyin, W., et al., *Inactivation of FAM20B causes cell fate changes in annulus fibrosus of mouse*
881 *intervertebral disc and disc defects via the alterations of TGF-beta and MAPK signaling pathways*.
882 *Biochim Biophys Acta Mol Basis Dis*, 2019. **1865**(12): p. 165555.

883 97. Ishikawa, H.O., et al., *Four-jointed is a Golgi kinase that phosphorylates a subset of cadherin*
884 *domains*. *Science*, 2008. **321**(5887): p. 401-404.

885 98. Perez, T.D. and W.J. Nelson, *Cadherin adhesion: mechanisms and molecular interactions*. *Handb*
886 *Exp Pharmacol*, 2004(165): p. 3-21.

887 99. Zygiel, E.M. and E.M. Nolan, *Transition Metal Sequestration by the Host-Defense Protein*
888 *Calprotectin*. *Annu Rev Biochem*, 2018. **87**: p. 621-643.

889 100. Wang, S., et al., *S100A8/A9 in Inflammation*. *Front Immunol*, 2018. **9**: p. 1298.

890 101. Dale, C.S., et al., *Analgesic properties of S100A9 C-terminal domain: a mechanism dependent*
891 *on calcium channel inhibition*. *Fundam Clin Pharmacol*, 2009. **23**(4): p. 427-38.

892 102. Dale, C.S., et al., *Effect of the C-terminus of murine S100A9 protein on experimental nociception*.
893 *Peptides*, 2006. **27**(11): p. 2794-802.

894 103. Hudson, B.I. and M.E. Lippman, *Targeting RAGE Signaling in Inflammatory Disease*. *Annu Rev*
895 *Med*, 2018. **69**: p. 349-364.

896 104. Garcia, V., Y.R. Perera, and W.J. Chazin, *A Structural Perspective on Calprotectin as a Ligand*
897 *of Receptors Mediating Inflammation and Potential Drug Target*. *Biomolecules*, 2022. **12**(4).

898 105. Ryckman, C., et al., *Proinflammatory activities of S100: proteins S100A8, S100A9, and*
899 *S100A8/A9 induce neutrophil chemotaxis and adhesion*. *The Journal of Immunology*, 2003.
900 **170**(6): p. 3233-3242.

901 106. Gopal, R., et al., *S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during*
902 *tuberculosis*. *American journal of respiratory and critical care medicine*, 2013. **188**(9): p. 1137-
903 1146.

904 107. Liu, Q., et al., *High levels of plasma S100A9 at admission indicate an increased risk of death in*
905 *severe tuberculosis patients*. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*,
906 2021. **25**: p. 100270.

907 108. Li, H.M., et al., *Altered NCF2, NOX2 mRNA Expression Levels in Peripheral Blood Mononuclear*
908 *Cells of Pulmonary Tuberculosis Patients*. *Int J Gen Med*, 2021. **14**: p. 9203-9209.

909 109. Leung, K., (99m)Tc-Diamine dioxime-Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys-polyethylene glycol, in
910 *Molecular Imaging and Contrast Agent Database (MICAD)*. 2004, National Center for
911 Biotechnology Information (US): Bethesda (MD).

912 110. Lin, Z., et al., *Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma*
913 *tumorigenesis by regulating β-catenin stability*. *Journal of Experimental & Clinical Cancer*
914 *Research*, 2018. **37**: p. 1-13.

915 111. Shi, W., et al., *Integrin beta5 enhances the malignancy of human colorectal cancer by increasing*
916 *the TGF-beta signaling*. *Anticancer Drugs*, 2021. **32**(7): p. 717-726.

917 112. Zhuang, H., et al., *Characterization of the prognostic and oncologic values of ITGB superfamily*
918 *members in pancreatic cancer*. *J Cell Mol Med*, 2020. **24**(22): p. 13481-13493.

919 113. Nurzat, Y., et al., *Identification of Therapeutic Targets and Prognostic Biomarkers Among Integrin*
920 *Subunits in the Skin Cutaneous Melanoma Microenvironment*. *Front Oncol*, 2021. **11**: p. 751875.

921 114. Zhang, L.Y., et al., *Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in*
922 *Glioblastoma*. *Front Oncol*, 2019. **9**: p. 904.

923 115. Ouchi, N., et al., *DIP2A functions as a FSTL1 receptor*. *J Biol Chem*, 2010. **285**(10): p. 7127-34.

924 116. Jin, X., et al., *Fstl1 promotes glioma growth through the BMP4/Smad1/5/8 signaling pathway*.
925 *Cellular Physiology and Biochemistry*, 2017. **44**(4): p. 1616-1628.

926 117. Murakami, K., et al., *Follistatin-related protein/follistatin-like 1 evokes an innate immune response*
927 *via CD14 and toll-like receptor 4*. *FEBS letters*, 2012. **586**(4): p. 319-324.

928 118. Horak, M., et al., *Follistatin-like 1 and its paralogs in heart development and cardiovascular*
929 *disease*. *Heart Fail Rev*, 2022. **27**(6): p. 2251-2265.

930 119. Zhang, Y., et al., *Circ-WDR27 regulates mycobacterial vitality and secretion of inflammatory*
931 *cytokines in Mycobacterium tuberculosis-infected macrophages via the miR-370-3p/FSTL1 signal*
932 *network*. *J Biosci*, 2022. **47**.

933 120. Zhang, W., et al., *Identification and characterization of DPZF, a novel human BTB/POZ zinc finger*
934 *protein sharing homology to BCL-6*. *Biochem Biophys Res Commun*, 2001. **282**(4): p. 1067-73.

935 121. Xie, Z., et al., *Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription*
936 *in liver*. *Proceedings of the National Academy of Sciences*, 2008. **105**(31): p. 10859-10864.

937 122. Xie, Z., et al., *Zbtb20 is essential for the specification of CA1 field identity in the developing*
938 *hippocampus*. *Proceedings of the National Academy of Sciences*, 2010. **107**(14): p. 6510-6515.

939 123. Zhang, Y., et al., *The zinc finger protein ZBTB20 regulates transcription of fructose-1, 6-*
940 *bisphosphatase 1 and β cell function in mice*. *Gastroenterology*, 2012. **142**(7): p. 1571-1580. e6.

941 124. Liu, X., et al., *Zinc finger protein ZBTB20 promotes Toll-like receptor-triggered innate immune*
942 *responses by repressing IκBa gene transcription*. *Proc Natl Acad Sci U S A*, 2013. **110**(27): p.
943 11097-102.

944 125. Arora, V., et al., *Primrose Syndrome*, in *GeneReviews*, M.P. Adam, et al., Editors. 1993, University
945 of Washington, Seattle: Seattle (WA).

946 126. Kim, S.H., et al., *Discoidin domain receptor 1 mediates collagen-induced nitric oxide production*
947 *in J774A.1 murine macrophages*. *Free Radic Biol Med*, 2007. **42**(3): p. 343-52.

948 127. Wang, H., et al., *DDR1 activation in macrophage promotes IPF by regulating NLRP3*
949 *inflammasome and macrophage reaction*. *Int Immunopharmacol*, 2022. **113**(Pt A): p. 109294.

950 128. Yeh, Y.C., H.H. Lin, and M.J. Tang, *Dichotomy of the function of DDR1 in cells and disease*
951 *progression*. *Biochim Biophys Acta Mol Cell Res*, 2019. **1866**(11): p. 118473.

952 129. Taciak, B., et al., *Evaluation of phenotypic and functional stability of RAW 264.7 cell line through*
953 *serial passages*. *PLoS One*, 2018. **13**(6): p. e0198943.

954 130. Ralph, P., J. Prichard, and M. Cohn, *Reticulum cell sarcoma: an effector cell in antibody-*
955 *dependent cell-mediated immunity*. *J Immunol*, 1975. **114**(2 pt 2): p. 898-905.

956 131. Zhang, X., et al., *DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4*
957 *to ARF6*. *Oncogene*, 2022. **41**(12): p. 1821-1834.

958 132. Su, H., et al., *Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome*.
959 *Nature*, 2022. **610**(7931): p. 366-372.

960 133. Ma, R., et al., *Discoidin domain receptors (DDRs): Potential implications in periodontitis*. *J Cell*
961 *Physiol*, 2022. **237**(1): p. 189-198.

962 134. Moll, S., et al., *DDR1 role in fibrosis and its pharmacological targeting*. *Biochim Biophys Acta Mol*
963 *Cell Res*, 2019. **1866**(11): p. 118474.

964 135. Sirvent, A., et al., *New functions of DDR1 collagen receptor in tumor dormancy, immune exclusion*
965 *and therapeutic resistance*. *Front Oncol*, 2022. **12**: p. 956926.

966 136. Marchioro, H.Z., et al., *Update on the pathogenesis of vitiligo*. *An Bras Dermatol*, 2022. **97**(4): p.
967 478-490.

968 137. Vilella, E., et al., *Expression of DDR1 in the CNS and in myelinating oligodendrocytes*. *Biochim*
969 *Biophys Acta Mol Cell Res*, 2019. **1866**(11): p. 118483.

970 138. Wu, M., *Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis*.
971 *Apoptosis*, 2003. **8**: p. 11-18.

972 139. Arlt, A. and H. Schäfer, *Role of the immediate early response 3 (IER3) gene in cellular stress*
973 *response, inflammation and tumorigenesis*. *European journal of cell biology*, 2011. **90**(6-7): p.
974 545-552.

975 140. Arlt, A., et al., *Expression of the NF- κ B target gene IEX-1 (p22/PRG1) does not prevent cell death*
976 *but instead triggers apoptosis in HeLa cells*. *Oncogene*, 2001. **20**(1): p. 69-76.

977 141. Sebens Müerköster, S., et al., *The apoptosis-inducing effect of gastrin on colorectal cancer cells*
978 *relates to an increased IEX-1 expression mediating NF- κ B inhibition*. *Oncogene*, 2008. **27**(8): p.
979 1122-1134.

980 142. Akilov, O.E., et al., *Enhanced susceptibility to Leishmania infection in resistant mice in the*
981 *absence of immediate early response gene X-1*. *J Immunol*, 2009. **183**(12): p. 7994-8003.

982 143. Leisching, G., et al., *RNAseq reveals hypervirulence-specific host responses to M. tuberculosis*
983 *infection*. *Virulence*, 2017. **8**(6): p. 848-858.

984 144. Coulter, L., K. Chawengsaksophak, and J. Rossant, *Endothelial cells and VEGF in vascular*
985 *development*. *Nature*, 2005. **438**(7070): p. 937-45.

986 145. Ferrara, N. and H.P. Gerber, *The role of vascular endothelial growth factor in angiogenesis*. *Acta*
987 *Haematol*, 2001. **106**(4): p. 148-56.

988 146. Ferrara, N. and K. Alitalo, *Clinical applications of angiogenic growth factors and their inhibitors*.
989 *Nat Med*, 1999. **5**(12): p. 1359-64.

990 147. Shibuya, M., *Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in*
991 *Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies*. *Genes Cancer*, 2011.
992 **2**(12): p. 1097-105.

993 148. Davuluri, K.S., et al., *Stimulated expression of ELR+ chemokines, VEGFA and TNF-AIP3 promote*
994 *mycobacterial dissemination in extrapulmonary tuberculosis patients and Cavia porcellus model*
995 *of tuberculosis*. *Tuberculosis (Edinb)*, 2022. **135**: p. 102224.

996 149. Delemarre, E.M., et al., *Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and*
997 *Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent*
998 *Tuberculosis*. *Front Immunol*, 2021. **12**: p. 725447.

999 150. Golubinskaya, E.P., et al., *Dysregulation of VEGF-dependent angiogenesis in cavernous lung*
1000 *tuberculosis*. *Pathophysiology*, 2019. **26**(3-4): p. 381-387.

1001 151. Harding, J.S., et al., *VEGF-A from Granuloma Macrophages Regulates Granulomatous*
1002 *Inflammation by a Non-angiogenic Pathway during Mycobacterial Infection*. *Cell Rep*, 2019. **27**(7):
1003 p. 2119-2131.e6.

1004 152. Tao, R.-H., et al., *Opposite effects of alternative TZF spliced variants on androgen receptor*.
1005 *Biochemical and biophysical research communications*, 2006. **341**(2): p. 515-521.

1006 153. Pioli, P.D., et al., *Zfp318 regulates IgD expression by abrogating transcription termination within*
1007 *the Igdm/Ighd locus*. *J Immunol*, 2014. **193**(5): p. 2546-53.

1008 154. Enders, A., et al., *Zinc-finger protein ZFP318 is essential for expression of IgD, the alternatively*
1009 *spliced Igh product made by mature B lymphocytes*. *Proceedings of the National Academy of*
1010 *Sciences*, 2014. **111**(12): p. 4513-4518.

1011 155. Schwickert, T.A., et al., *Ikaros prevents autoimmunity by controlling anergy and Toll-like receptor*
1012 *signaling in B cells*. *Nat Immunol*, 2019. **20**(11): p. 1517-1529.

1013

1014
1015 **Figure 1. Mouse survival following exposure to a low dose of aerosolized *M. tuberculosis* strain**
1016 **Erdman.** Diversity Outbred (DO) mice ($n = 680$, brown solid line), and the eight inbred founder strains (n
1017 = 15 to 78, colored lines) were infected with *M. tuberculosis* strain Erdman bacilli by aerosol. Panel A
1018 shows cumulative survival extending to nearly 600 days post infection. Approximately 30% of the DO
1019 population succumbed to pulmonary TB by 60 days post infection. Of the eight inbred founder strains,
1020 survival studies were completed for the C57BL/6J inbred strain; the other seven inbred founder strains
1021 were euthanized 40 days after *M. tuberculosis* infection. No inbred founder strain or non-infected (NI) DO
1022 mice ($n = 53$, dashed line) showed mortality within the same period. Panel B shows the daily mortality for
1023 *M. tuberculosis*-infected DO mice, highlighting the early wave of mortality that peaked between 25- and
1024 35-days post infection.

1025
1026 **Figure 2. Diversity Outbred (DO) mice develop a spectrum of histopathological lung due to *M.***
1027 ***tuberculosis* infection.** Lung lobes were formalin-fixed, paraffin-embedded, sectioned, and stained with
1028 hematoxylin & eosin. Panel A: Lung section from a non-infected DO mouse. Panels B through I: Lung
1029 sections from *M. tuberculosis*-infected DO mice euthanized eight weeks after infection show a spectrum
1030 of lesions from mild to severe (upper left to bottom right); focal lesions (e.g., Panel B) to diffuse infiltration
1031 (Panel H); and include necrotizing (Panels C, E, F, I) and non-necrotizing granulomas (Panels B, D, G,
1032 H). Low magnification (15X).

1033
1034 **Figure 3. Weight loss, granuloma necrosis, and lung cytokines/chemokines are induced by *M.***
1035 ***tuberculosis*-infection of Diversity Outbred (DO) mice and correlate with each other.** (A) Traits in
1036 *M. tuberculosis*-infected DO mice are higher, with much wider ranges, compared to uninfected DO mice.
1037 Each panel shows a boxplot for one phenotype, separated by infection status. Boxes represent the inter-
1038 quartile range; center bar is the median and whiskers cover 90% of the data. T-test p-values are shown
1039 in each plot. (B) Many traits measured in *M. tuberculosis*-infected DO mice are positively correlated with
1040 each other. The lower triangle shows Pearson correlation of pairs of phenotypes. The upper triangle
1041 shows these correlations as ellipses, with narrower ellipses indicating higher correlation. All values are
1042 colored based on the scale to the left of the plot. Traits are hierarchically clustered on both axes.

1043
1044 **Figure 4. Heatmap of linkage mapping peaks shows patterns of common genetic regulation.** The
1045 mouse genome, from chromosome 1 through X, is shown on the horizontal axis. Phenotypes are shown
1046 on the vertical axis. Each cell shows the LOD score on one chromosome for the phenotype listed on the
1047 left, colored by the color scale. The phenotypes are hierarchically clustered based on the correlation
1048 between LOD curves, i.e., phenotypes with similar LOD curves are clustered next to each other.

1049
1050 **Figure 5 Overview of gene prioritization methods.** Traits were mapped to identify positional candidate
1051 genes in QTLs. Gene expression data were analyzed for differential gene expression. The top 500
1052 differentially expressed genes (DEG) were used to train SVMs to distinguish these trait-related genes
1053 from other genes in the genome using the FNTM mouse lung network. The fitted models were used to
1054 score positional candidates in each trait QTL. Positional candidates were then ranked as trait-related
1055 based on their functional scores.

1056
1057 **Figure 6. Quantitative Trait Locus (QTL) mapping results of first principal component (PC1) of**
1058 **CXCL1, CXCL2, *M. tuberculosis* burden, and MMP8 identifies *Dots1* on chromosome 1, containing**
1059 **the gene candidates *Fam20b* and *Ncf2*.** Panel A shows the LOD curve for PC1 between 150 and 160
1060 Mb on chromosome 1 with peak near 155.36 Mb. Panel B shows the founder allele effects for PC1 in the
1061 same genomic interval. Each colored line is the best linear unbiased predictor for one of the founder
1062 alleles. Founder colors are shown in the upper left. Panel C shows the LOD score of the imputed SNPs
1063 in the same genomic interval. Each point represents the LOD score of one imputed SNP. Panel D shows
1064 the genes in the confidence interval. Panel E shows the functional scores for genes in the chromosome
1 QTL. Each dot represents a single gene. Its position on the x axis is its position within the QTL. Its

1065 position on the y axis is the functional -log10(UPPR) derived from the SVM. Points are colored based on
1066 which trait the functional score corresponds to - green with CXCL1, orange with MMP8, and blue with *M.*
1067 *tuberculosis* burden. *Fam20b* and *Ncf2* genes had the highest functional scores.
1068

1069 **Figure 7. Quantitative Trait Locus (QTL) mapping of lung S100A8 identifies Dots3 on chromosome**

1070 3, containing the gene candidates *S100a8* and *S100a9*. Panel A shows the LOD score in the
1071 confidence interval from 90 to 92 Mb on chromosome 3. Panel B shows the founder allele effects within
1072 the confidence interval. Panel C shows the LOD score of the imputed SNPs with the highest SNPs
1073 colored in red. Panel D shows the gene in the same interval. The gene *S100a8* is directly under the SNPs
1074 with the highest LOD scores. Panel E shows the functional scores for genes in the chromosome 1 QTL.
1075 Each dot represents a single gene. Its position on the x axis is its position within the QTL. Its position on
1076 the y axis is the functional -log10(UPPR) derived from the SVM. The gene *S100a8* had the highest
1077 functional score.
1078

1079 **Figure 8. Quantitative Trait Locus (QTL) mapping results of first principal component (PC1) of *M.***

1080 *tuberculosis* burden, weight loss, and granuloma necrosis identifies Dots5 on chromosome 16,

1081 containing gene candidates *Fstl1*, *Itgb5*, and *Zbtb20*. *M. tuberculosis* lung burden, weight loss, and
1082 granuloma necrosis map to a region on chromosome 16 near 38 Mb. Panel A shows the LOD profile for
1083 *M. tuberculosis* in the confidence interval. Genomic position on chromosome 16 is on the horizontal axis
1084 and the LOD score is on the vertical axis. Panel B shows the founder allele effect in the confidence
1085 interval. The vertical axis shows the estimates effect of gaining one founder allele. Panel C shows the
1086 SNP LOD score for association mapping using imputed SNPs. Panel D shows the genes in the
1087 confidence interval. Panel E shows the functional scores for genes in the chromosome 16 QTL. Each dot
1088 represents a single gene. Its position on the x axis is its position within the QTL. Its position on the y axis
1089 is the functional -log10(UPPR) derived from the SVM. Points are colored based on which trait the
1090 functional score corresponds to - green with weight loss and blue with *M. tuberculosis* burden. *Fstl1* was
1091 the top ranked gene overall followed by *Itgb5* and *Zbtb20*.
1092

1093 **Figure 9. Quantitative Trait Locus (QTL) mapping results of first principal component (PC1) of**
1094 **granuloma necrosis, *M. tuberculosis* burden, weight loss, CXCL1 and MMP8 identifies Dots7 on**
1095 **chromosome 17, which contains gene candidates *Ier3*, *Ddr1*, and *Zpf318*.** Panel A shows the LOD
1096 score for PC1 of lung granuloma necrosis ratio, *M. tuberculosis* burden, MMP8, CXCL1, and weight loss
1097 in the interval where the phenotypes map. Panel B shows the founder allele effects for the two peaks.
1098 Panel C shows the LOD score of the imputed SNPs in the interval, with the highest scoring SNPs colored
1099 in red. Panel D shows the locations of the genes in the interval. Panel E shows the functional scores for
1100 genes in the chromosome 17 QTL. Each dot represents a single gene. Its position on the x axis is its
1101 position within the QTL. Its position on the y axis is the functional -log10(UPPR) derived from the SVM.
1102 Points are colored based on which trait the functional score corresponds to - blue with CXCL1 and green
1103 with granuloma necrosis. *Vegfa* was the top ranked gene overall followed by *Ier3*, *Ddr1*, and *Zpf318*.
1104

1105 **Supplemental Figure 1. Mouse body weight following a low dose of aerosolized *M. tuberculosis***
1106 **strain Erdman.** Mice were infected with a low dose of *M. tuberculosis* strain Erdman by aerosol. Body
1107 weight of identically housed, age-, gender-, and generation-matched non-infected Diversity Outbred (DO)
1108 controls (n = 49) compared to baseline are shown over time (A). Body weight changes of Progressor DO
1109 mice (n = 195); Controller DO mice (n = 145); and C57BL/6J inbred founder strain mice that succumbed
1110 to pulmonary TB (n = 39), are shown over time compared to pre-infection baseline (B, C, D). All mice
1111 were weighed 1 to 3 days prior to *M. tuberculosis* infection, at least twice per week throughout infection,
1112 and immediately before euthanasia. Each line is the body weight expressed as a percentage of initial
1113 pre-infection body weight.
1114

1115
1116 **Supplemental Figure 2. Clinical correlates of survival due to pulmonary TB in Diversity Outbred**
1117 **(DO) mice following exposure to a low dose of aerosolized *M. tuberculosis* strain Erdman.** Age-,
1118 gender-, and generation-matched DO mice were assigned to cages at random, and infected (or not
1119 infected) with a low dose of *M. tuberculosis* strain Erdman by aerosol exposure. All mice were initially
1120 weighed 1-3 days prior to infection, at least twice per week during infection, and immediately before
1121 euthanasia. Panel (A) shows retrospective analysis of initial body weights of Non-infected mice (n = 76)
1122 compared to pre-infection body weights of Progressors (n = 298) and pre-infection body weights of
1123 Controllers (n = 195), shown as box-and-whisker plots with the line at the mean for each group, and
1124 whiskers at the minimum and maximum. Data were analyzed by 1-way ANOVA with Tukey's multiple
1125 comparisons test ***p<0.001; ****p<0.0001. Panel B shows the rate of weight loss (gm/day) and duration
1126 of body weight (BW) loss in days were negatively correlated. Panel C shows the duration of BW loss was
1127 strongly, positively, and linearly correlated with survival by Spearman correlation analysis (r = 0.848 with
1128 dashed lines indicating the 95% confidence interval, 0.8204 to 0.8717, p<0.0001). Panel D is a correlation
1129 matrix to show how survival and 8 clinical indicators of pulmonary TB in Diversity Outbred mice correlate
1130 with each other. Only correlations with p-values <0.00001 are shown on the matrix. Cells marked by an
1131 "X" were not significantly correlated.

1132
1133 **Supplemental Figure 3. Examples of necrotizing and non-necrotizing lesions in *M. tuberculosis***
1134 **infected Diversity Outbred (DO) mice.** Lung lobes were formalin-fixed, paraffin-embedded, sectioned,
1135 and stained with carbol fuschin and counterstained with hematoxylin & eosin. Panels A and B: High
1136 magnification images of necrotizing lung lesions. One example contains abundant pyknotic nuclear debris
1137 (A) and one example contains abundant fibrin, eosinophilic cellular debris, and less nuclear debris (B).
1138 Panels C and D: High magnification images of non-necrotizing lung lesions. Both examples contain
1139 predominantly viable cells, including macrophages, foamy macrophages, and foci of lymphocytes (400X).


1140
1141 **Supplemental Figure 4. Common founder allele effects for four traits on distal chromosome 1**
1142 **QTL.** Founder allele effects of the four phenotypes with genetic mapping peaks having LOD > 6.0 on
1143 chromosome 1 at 155.36 Mb. All four phenotypes have similar allele effects. Each panel shows the
1144 founder allele effects for the phenotype listed in the title. Founders are on the horizontal axis and the
1145 standardized allele effect are on the horizontal axis.

1146
1147 **Supplemental Figure 5. Receiver operator characteristic (ROC) curves for SVM training on traits**
1148 **used in gene prioritization.** Each panel shows the true positive rate of the trained SVM as a function of
1149 the false positive rate for each trait. The area under the curve (AUC) is noted for each panel.


1150
1151 **Supplemental Figure 6. Validation of QTL mapping results.** Panel A: *M. tuberculosis* infected
1152 Diversity Outbred (DO) mice with one or more PWK/PhJ alleles at the mouse H-2 locus on chromosome
1153 17 in *Dots8* (near 36 Mb) have significantly reduced survival compared to DO mice carrying other alleles
1154 (p = 0.00075, Cox-PH test). Kaplan-Meier curves of survival of *M. tuberculosis* infected mice carrying
1155 PWK/PhJ allele (red) or any other founder allele (black). Days of survival is shown on the horizontal axis
1156 and the proportion of mice surviving is shown on the vertical axis. Panel B: Lungs from *M. tuberculosis*
1157 infected CAST/EiJ inbred mice contain significantly more S100A8 protein (calgranulin A) than lungs of
1158 PWK/PhJ inbred mice. PWK/PhJ (red) and CAST/EiJ (green) inbred founder strains with 4-6 mice per
1159 strain time point, analyzed by Mann-Whitney t-tests within each time point, *p<0.05. Panel C: *M.*
1160 *tuberculosis* infected S100a8 knockout (KO), heterozygotes (HET), wild-type (WT) C57BL/6 inbred mice
1161 were euthanized at the time points indicated on the X-axes, and *M. tuberculosis* lung burden assessed
1162 by CFUs with total combined 15-22 mice per genotype per time point from 2 independent experiments,
1163 shown as average and standard error of the mean. No significant (ns) differences were identified within
1164 each time point by mixed effects ANOVA with Tukey's post-test (p<0.05). Panel D shows *M. tuberculosis*
1165 burden in the lungs of PWK/PhJ (red) and CAST/EiJ (green) inbred founder strains with 4-6 mice per
1166 strain time point. No significant differences were identified by Mann-Whitney t-tests within each time point,

1166 although there was a trend for higher bacterial burden at day 20 post infection in lungs from CAST/EiJ
1167 inbred mice as compared to PWK/PhJ.
1168
1169 **Supplemental File 1** This file is an Excel workbook containing worksheets that list all protein-coding
1170 genes in each QTL with the functional candidates highlighted.
1171
1172 **Supplemental File 2** This is an Excel fie that lists the top 10 functional candidates for each trait in each
1173 QTL.
1174
1175 **Supplemental File 3** This is an Excel file that lists genes within chromosome 17 QTL.

A



B



Day post *M.tb* infection (20±12 bacilli by aerosol)

Figure 1




Figure 2





Figure 3




Figure 4







Figure 5



<https://doi.org/10.1101/2023.12.21.572738>
 (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to
 available under aCC-BY 4.0 International license.







Figure 7

A




B



C



D



E




Figure 8




Figure 9




Figure 6